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Angiotensin converting enzyme inhibitors (ACEi) are routinely used as first line treatment for 
hypertensive patients because of their protective effects against heart and kidney disease. 
Despite their clinical benefits, ACEi used is associated with adverse side effects such as life 
threatening angioedema (ACEi-AE) and persistent dry cough (ACEi-cough). The aetiology of 
ACEi-AE remains unresolved. Currently there is no marker to predict which patients using 
ACEi will develop ACEi-AE. Advances in ACEi-AE research have proposed that increased 
plasma bradykinin (BK) levels are associated with ACEi-AE.  BK acts on widely expressed 
bradykinin type 2 receptors (BKR-2) resulting in the activation of proinflammatory 
responses and nitric oxide generation. Furthermore, it has been shown that ACEi-AE is 
associated with significantly low plasma aminopeptidase P, an enzyme that plays a crucial 
role in BK degradation during ACE inhibition. It was also shown that C2399A single 
nucleotide polymorphism (SNP) at XPNPEP2 was a significant predictor of APP activity in 
Caucasians. 
In this study the analysis of the association between ACE insertion (I)/deletion (D) 
polymorphism, XPNPEP2 C2399A SNP, BKR-2 +9/-9 polymorphism and C-58T SNP were 
examined in 77 controls, 52 ACEi-AE patients and 36 ACEi-cough patients.  Furthermore 
activities of ACE and APP were determined in serum of 29 controls, 52 ACEi-AE patients 
and 36 ACEi-cough patients and correlated with genotype. 
The results revealed no significant association between ACE-II genotype and ACEi-AE and 
ACEi-cough. Similarly, the ACEi-AE and ACEi-cough patients showed significantly lower A 
allele incidence compared to controls. The BKR-2 -9 allele was significantly associated with 
ACEi-AE and not ACEi-cough. The -58T allele displayed no significant association with both 
ACEi-AE and ACEi-cough. 
 The ACE activity in serum was significantly decreased in cough and AE subjects compared 
to controls. Surprisingly, the ACE activity was similar in all patients when correlated with 
genotype (II, ID, DD) contrary to the expected increase in ACE activity usually observed in 
patients with DD genotype.  
APP activity was measured in serum using a fluorimetric enzyme assay. The APP activity 














However, when APP activity was correlated with the genotype (A, AC, C), there was no 
significant difference in APP activity in all groups. These data suggest that other genetic and 
biochemical differences in our population might explain the phenotypic variability of the 















Angiotensin I-converting enzyme inhibitors (ACEi) are widely used in the treatment 
hypertension, myocardial infarction, congestive heart failure and diabetic nephropathy. These 
drugs improve patient clinical outcomes; and reduce morbidity and mortality. Hence they are 
often used as first line of treatment. Although clinically effective, ACEi are associated with 
side adverse effects such as persistent dry cough (ACEi-cough) and a potentially life-
threatening angioedema (ACEi-AE) [1]. Given that 35-40 million people worldwide are 
currently taking ACEi, the number of people at risk for ACEi-AE is substantial [2].           
 
1.1 ACE Protein and Role in Renin-Angiotensin-Aldosterone System  
Angiotensin I converting enzyme (ACE) is a zinc dipeptidyl caboxypeptidase widely 
distributed on the surface of epithelial and endothelial cells. Furthermore it plays a crucial role 
in blood pressure regulation through its action in the renin-angiotensin-system (RAAS) 
(figure1.1) and kinin-kallikrein-system (KKS). Conditions such as reduced renal perfusion, 
sympathetic activation, and increased loss of salt stimulate the juxtaglomerular cells of the 
kidney to produce the aspatyl protease, renin (figure 1.1).  The precursor peptide, 
angiotensinogen (AGT)  produced by the liver is converted to vasoinactive peptide 
angiotensin I (AngI) by renin [3]. AngI is then cleaved by ACE to produce a potent 
vasoconstrictor angiotensin II (AngII) (figure1.1). AngII then exerts its important 
physiological actions at several sites including the vascular cells, smooth muscle cells, the 
adrenal cortex, kidney and brain through its type 1 (AT1R) and type 2 (AT2R) receptors.  
AngII plays a key role in fluid and electrolyte balance as well as maintenance of arterial blood 
pressure [4]. Other physiologic responses of AngII include increased release of epinephrine 
and norepinephrine as well as stimulation of thirst and increased secretion of anti-diuretic 
hormone and adrenocorticotrophic hormone.  AngII further acts on the zona glomerulosa of 
the adrenal cortex to stimulate the release of aldosterone, which in turn activates the 
epithelium sodium channel in the collecting duct of the kidney, resulting in sodium retention, 
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cytokines and growth factors and thus promotes cell growth and proliferation. Thus AngII 
plays a crucial role in the development of atherosclerosis and vessel wall change due its 
growth effects. 
 
Figure 1.1: Schematic presentation of the renin-angiotensin-aldosterone system. 
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1.2 The Kinin-Kallikrein System 
The KKS is a complex system composed of pharmacologically active low-molecular-weight 
vasoactive kinins such bradykinin (BK), kallidin and methionyl-lysl-bradykinin. Kinins are 
released into body fluids and tissues due to enzymatic cleavage of precursor kininogens by 
serine proteases known as kallikreins. These peptides play a key role in inflammation due to 
their ability to activate endothelial cells and consequently lead to vasodilation, increased 
vascular permeability, nitric oxide production and arachidonic acid mobilization. Kinins have 
been shown to stimulate nerve endings and thus leading to burning dysethesia(6). Hence 
classical parameters of inflammation can be attributed to kinin formation[6].   
 
1.2.1 Bradykinin Formation 
Two distinct biological pathways are responsible for the generation of BK (figure 1.2). The 
first has of two components namely: an enzyme tissue kallikrein (TK) and a plasma substrate 
low-molecular-weight-kininogen (LMWK)[7]. TK has wide tissue distribution and is 
processed intracellularly from precursor prokallikrein. It digests LMWK to yield a 
decapeptide, Lys-bradykinin (kallidin). Plasma aminopeptidases then cleave the N-terminal 
Lys resulting in the formation of nonapeptide BK[6]. 
The second pathway is a complex biological system that forms part of the initiating 
mechanism for the activation of the intrinsic coagulation pathway[7]. The initiating protein, 
factor XII (fXII) binds to negatively charged macromolecular surfaces and autoactivates to 
form factor XIIa (fXIIa)[8].  Plasma substrates for fXIIa are prekallikrein and factor XI (fXI) 
that circulate complexed with high-molecular-weight- kininogen (HMWK). These complexes 
also attach to the initiating surfaces with the major attachment sites being on the two domains 
of HMWK[9]. This then places both prekallikrein and fXI in optimal conformation for 
cleavage to plasma kallikrein (PK) and fXIa. It is worth mentioning that TK and PK are 
separate gene products and have little sequence homology though they have related functions. 
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cleaves HMWK. The two kininogens are homologous starting at the N-terminus and 
continuing to twelve amino acids beyond the BK moiety only differing at the C-terminus due 
to alternative splicing[10]. BK is a potent vasodilator that is converted to an inactive 
metabolites primarily by ACE[11] and secondarily aminopeptidase P [12]. A small fraction 
of BK or kallidin (3.5%) is converted into a potent proinflammatory peptide, des-Arg9-BK or 
des-Arg10kallidin by carboxypeptidase N, which are then inactivated by ACE and 
aminopeptidase P (APP) [12]. BK and kallidin act on constitutively expressed B2 receptors 
whereas des-Arg9-BK or des-Arg10kallidin act on B1 receptors, only induced as result of 




Figure1.2: Pathways for formation and degradation of bradykinin. LMWK, low molecular 
weight kininogen; TK, tissue kallikrein; HMWK, high molecular weight kininogen; PK, 
plasma kallikrein; APP, aminopeptidase P; ACE, angiotensin converting enzyme. 
LMWK Surface 
FXII, Prekallikrein, HMWK 
J. 
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1.2.2 Bradykinin Receptors, Signalling and Physiologic Actions of BK 
Bradykinin receptors (BKRs) are G protein-coupled receptors belonging to the seven 
transmembrane domain family.  Two BKRs have been identified, namely type 1 (BKR-1) and 
type 2 (BKR-2), based on their pharmacological properties and on expression cloning[14]. 
The BKR-1 gene is located on chromosome 14q32.1-q32.2 whilst BKR-2 gene has been 
mapped to chromosome 1432q. The two receptors share 36% amino acid sequence homology 
[15]. BKR-1 is synthesized de novo in various tissues following injury, whereas BKR-2 is 
constitutively expressed in many tissues including neurons of the brain stem, basal nuclei, 
cerebral cortex, thalamus and hypothalamus. Though BKR-1 is induced under inflammatory 
states, it has been recently shown that these receptors centrally mediate nociception 
suggesting their constitutive presence in the brain and/or spinal cord[16].  
BK is a potent vasodilator that leads to the liberation of vasodilatory mediators such as nitric 
oxide (NO), prostacyclin (PGI2) and endothelium-derived hyperpolarizing factor 
(EDHF)[17]. BKR-2, expressed on the endothelial cells leads to activation of phospholipase 
C gamma via transient tyrosine phosphorylation causing increased liberation of inositol 1,4,5-
triphosphate (IP3) and diacylglycerol[18]. Increased IP3 then raises intracellular calcium (Ca) 
by liberation from internal stores or by an increased Ca influx and thus leading to the 
activation of the  Ca sensitive endothelial nitric oxide synthase (eNOS)[19]. Additionally, 
elevated Ca activates Ca sensitive phospholipase A2, which  hydrolyzes membrane 
phospholipids to liberate arachidonic acid[20]. Furthermore, BK signalling also activates 
tyrosine kinase 2 (Tyk2) of the Janus-activated kinase (JAK) family resulting in 
phosphorylation and nuclear translocation of STAT3[21]. It was also shown that BK 
activates protein kinase A thus leading to acute increase of NO due to phosphorylation of 
eNOS at Ser179 [22]. 
Cardiovascular actions of BK such as release of NO, PGI2 and EDHF as well as release of 
tissue plasminogen activator (tPA) are mediated via the BKR-2 (figure 1.3). BK also 
displays cardio-protective effects by preconditioning tissue for protection against myocardial 
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effects on cardiomyocytes[24]. Moreover BK has been shown to enhance insulin-dependent 
increase from pancreatic " cells through increase of intracellular calcium in response to 
hyperglycemia[25].  
 
Figure 1.3: Mechanism of Bradykinin induced activation on vascular endothelial cells. Nitric 
oxide and prostacyclin act in an autocrine and paracrine manner. BKR-2, bradykinin type 2 
receptors; JAK, Janus activated kinase; PLC, phospholipase C; DAG, diacylglycerol; IP3, 
Inositol triphosphate; ER, endoplasmic reticulum; Ca2+, calcium; NO+, nitric oxide; eNOS, 
epithelial nitric oxide synthase; EDHF, epithelial dihyperpolarizing factor;PGH2, 
prostaglandin;PGI2, prostacyclin; AC, adenyl cyclase; ATP, adenine tri-phosphate; cAMP, 
cyclic adenine monophosphate; sGC, guanine cyclase synthase; GTP, guanine tri-phosphate; 
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1.3 Interaction between the RAAS and the KKS 
The first recognized important link between the RAAS and the KKS was the previously 
mentioned bifunctional activity of ACE to cleave BK into inactive peptides and convert AngI 
to the biologically active octapeptide AngII (figure 1.4). Moreover BK has been shown to be 
a preferred substrate of ACE over AngI with a Km of 0.18#M and a catalytic efficiency ~20 
times higher([26;27]. Angiotensin converting enzyme 2 (ACE2), is an ACE homologue that 
has recently been discovered and was shown to have different substrate specificity than ACE 
[28;29].  Located mainly in the heart, kidney and testis, ACE2 is a caborxypeptidase that 
degrades AngI to angiotensin 1-9  (Ang1-9) and AngII to a heptapeptide angiotensin 1-7 
(Ang1-7) [30].  Ang1-9 enhances arachidonic acid release by BK and resensitizes BKR-2 
[28;31]. Before ACE2 was discovered, angiotensinase C or prolylcarboxypeptidase (PRCP), a 
serine protease had been known to degrade AngII with Km of 2mM [32], however ACE2 has 
been shown degrade AngII more efficiently [32;33]. Ang1-7 counteracts vasoconstrictor 
effects of angiotensin II by stimulating NO and PGI2 release thereby causing vasodilation. 
ACE and ACE2 have different specifities for BK, whereas ACE degrades BK, ACE2 does not 
cleave BK but can degrade des-Arg9-BK[34]  The physiological implication of this finding 
remains to be elucidated. 
 
1.3.1 The Role of PRCP, TK and PK 
Recently it has been shown that PRCP is an endothelial activator of PK where PK assembles 
to be active and thus indicating another interaction between the RAAS and the KKS[35]. 
PRCP the first identified endothelial cell activator of PK activates PK independent of 
fXIIa[35]. PRCP activates PK at Km 7-17nM suggesting that PRCP is better activator than an 
angiotensin degrading enzyme[35;36]. Furthermore activation of PK leads to BK formation.  
Over 20 years ago both PK and TK were proposed to be proteolytic activators of plasma 
prorenin[37]. Prorenin is the inactive precursor of renin composed of a 43 amino acid N-
terminus prosegment that covers the enzymatic cleft and obstructs substrate access. However 
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PK required acid inactivation of plasma protease inhibitors and contact activation of fXII[38]. 
However, prorenin can be activated by PK at neutral pH though some mechanism of plasma 
protease inhibitor inactivation is required[38]. Furthermore, it was shown that a patient with 
decreased total kininogen had reduced plasma renin elevation when assuming the upright 
position post salt loading[39]. Thus leading to the notion that PK participates in prorenin 
expression. Though TK has been proposed as a prorenin activator, there is little evidence on 
how tissue prokallikrein is activated. However, porcine pancreatic kallikrein activates 
prorenin at pH 8.5[40]. Mouse tissue kallikriens mK1, mK9, mK13 and mK22 have been 
shown to activate prorenin and additionally human hK1 activates prorenin[41;42]. Whilst TK 
and PK along with cathespin B and PC5 proteolytically activate prorenin, it is still not clear 
as to which enzyme converts prorenin to renin[43;44]. Interestingly, it was shown that  TK 
knockout mouse had reduced renal renin mRNA compared with wild type and on the other 
hand BKR-2 knockout mice had increased renin mRNA[45]. The meaning of these data, 
however remains unclear although it is possible that  TK could be a promoter of renin gene 
expression whereas PK may have a role in renin activation[30]. Additionally prorenin has 
been recently shown to be activated non-proteolycally in experimental vascular smooth 
muscle cells. This mechanism leads to prorenin binding to the recently identified 
prorenin/renin receptor. This enhances the efficiency of AGT cleavage by renin by unmasking 
prorenin catalytic activity. Prorenin bound to the receptor cleaves AGT with kinetics similar 
to that of the fully active renin in solution without the proteolytic removal of its prosegment. 
 
1.3.2. Interaction between Ang 1-7 and BK 
Another area of interaction between the two systems is the influence of BK and Ang1-7 on 
the vasculature. Ang1-7 is breakdown product of AngII by ACE2, PRCP, neprilysin (NEP) 
and endopeptidase 24.15[32;33;46;47]. Each of the enzymes also plays a role in BK 
degradation, whether direct or indirect. Ang1-7 exerts its biological effects by binding to 
AT1R to block AngII or by stimulating AT2R. It has been recently shown that a G protein-
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to angiotensin 1-5. Biologically, Ang1-7 leads to BK potentiation and mediation of vascular 
activity of BK[49]. Moreover Ang1-7 augments BK by locally acting as a synergistic 
regulator of kinin induced vasodilation by inhibiting ACE and releasing NO. Thus Ang1-7 is 
both a substrate and inhibitor of ACE[50]. Both Ang1-7 and Ang1-9 potentiate BK effects 
by inducing crosstalk between ACE and BKR-2[31]. 
 
1.3.3 Interactions between the RAAS and KKS at Receptor Level. 
Both AT1 and AT2R have been implicated in the crosstalk between the RAAS and the KKS. 
The RAS has been shown to stimulate renal BK production and cGMP formation via the 
AT2R[51]. During salt depletion, renin inhibition and not the AT2R inhibition results in 
reduced renal BK levels, thus leading to the notion that stimulation of the AT2R releases BK 
and NO[51]. Liu et al showed in experimental heart failure that ACE inhibition and AT1R 
blockade have cardioprotective effects that are due to direct effects on the heart as well as 
secondary haemodynamics mediated by BK formation via activation of the AT2R[52].  How 
the AT2R system leads to increased BK formation remains unclear. However, it might be 
mediated by increased TK expression or alternatively by increased PRCP, PK or HMWK 
expression[30;53]. Interestingly, the AT1R has been shown to interact with BKR-2[54;55].  
This interaction leads to formation of stable heterodimers causing increased activation of G!q 
and G!i proteins[54]. Heterodimerization also leads to the alteration in the endocytic 
pathways of both receptors[54]. Interestingly, it has been shown that AT2R and BKR-2 
heterodimerization leads to a 4-5 fold increase in BKR-2 protein levels in pre-eclamptic 
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1.3.4 Role of the Interactions between the RAAS and the KKS in Thrombosis, 
Fibrinolysis and Angiogenesis. 
Already mentioned as an important modulator of vascular biology and blood pressure 
homeostasis, the KKS and the RAAS play a crucial role in thrombosis, fibrinolysis and 
angiogenesis. The RAS has been postulated to be a prothrombotic system[56]. AngII has 
been shown to increase plasminogen activator inhibitor-1 (PAI-1) mRNA, antigen and active 
protein levels in both cultured astrocytes and endothelial cells[57]. Furthermore AngII also 
increases tissue factor (TF) mRNA and activity without affecting tissue factor protease 
inhibitor (tPA) in rat aortic endothelial cells[58]. Interestingly, artrial natriuretic peptide 
abolishes AngII-induced expression of TF and PAI-1.[59] Additionally adrenomedullin, a 
vasodilating peptide also blocks AngII upregulation of TF and PAI-1 mRNA[57]. Activation 
of MEK/ERK and Rho-kinase pathways in cultured smooth muscle cells contributes to AngII 
–induced PAI-1 mRNA increase[60].  Moreover, AngII increases TF mRNA and antigen but 
not PAI-1 in cultured human monocytes[61]. 
In contrast to the RAS, the KKS has been known to be fibrinolytic[30]. Deficiency of fXII 
was shown to cause defective fibrinolysis[62].  PK, fXIIa, and fXIa have the ability to 
activate plasminogen to plasmin, although much less efficiently than tissue-type plasminogen 
activator and two chain urokinase plasminogen activator[8;63;64]. Nonetheless, PK has been 
shown to activate single chain urokinase[40]. Activation of PK bound HWMK on endothelial 
cells leads to kinetically favorable single chain urokinase formation with subsequent formation 
of plasmin[40;65]. In addition to stimulating fibrinolysis through single chain urokinase 
activation, PK induced BK formation influences fibrinolysis by stimulating tPA release from 
the venous endothelium[66;67]. This mechanism is mediated via BKR-2 and is independent of 
NO and PGI2 liberation induced by BK[68]. BK also stimulates cyclooxygenase 2 (COX2) 
together with PGI2 thereby contributing to the anticoagulant state[69;70]. COX2 stimulation 
also results in increased renal medullary blood flow, increased urinary output, and reduced 
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Furthermore, the KKS contributes to the antithrombotic state via the activity of HMWK and 
LWMK. Both HMWK and LMWK were shown inhibit thrombin-induced platelet 
aggregation[71]. Furthermore, it was shown that a patient with plasma that is deficient with 
total kininogen had lower threshold of gamma thrombin-induced platelet activation than 
normal[72].  ACE has been shown to degrade BK to BK-(1-5) and this breakdown product 
also inhibits thrombin[73]. 
The role of the RAS and the KKS in angiogenesis has recently been established.  It has been 
known for a while that BK may have some proangiogenic effects with BK having being 
shown to stimulate a neovascular response in implanted sponges in experimental rat model 
with the new vessel formation being blocked by [Leu8]des-Arg9-BK[74]. Moreover, intact 
HMWK and LMWK proteins are also proangiogenic[75]. Recently HMWK-induced 
angiogenesis was blocked by targeting its 5th domain with monoclonal antibody and thus 
interfering with PK cleavage of HMWK to liberate BK[76;77].Furthermore, gene transfer of 
human TK to BKR-2 deficient mice augmented capillary density and restoration of the 
physiologic angiogenic response required for wound healing in this animal[78].  Moreover, 
gene transfer of TK also resulted in increased urinary kinin cGMP and cAMP and showed a 
protective effect on neointima formation[78]. Therefore either upregulating the KKS or 
interfering with the RAS influences angiogenesis. Interaction between BK and AngII is 
essential for normal cardiac development. BKR-2 deficient mice treated with AT1R 
antagonist from birth were shown to have reduced left ventricular mass, chamber volume, wall 
thickness, and myocardial fibrosis than untreated mice suggesting the intimate involvement of 
AngII in cardiac development[79;80].  The RAS components are closely involved in 
reparative angiogenesis. AT1R was shown to be necessary for reparative angiogenesis in limb 
ischaemia models[81]. In addition to AngII and BKR-2, other components of the RAS and the 
KKS also contribute to angiogenesis.  BKR-1 also participates in reparative angiogenic 
process[30]. Cultured cells stimulated with BKR-1 initiate endothelial cell proliferation and 
survival, while antagonizing the BKR-1 results in apoptosis[82]. Lastly AGT and its 
breakdown products interfere with angiogenesis[83]. AGT is a serpin and an antithrombin 
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[reactive loop cleaved form] and des [AngI] AGT have antiangiogenic activity[83]. In 
summary, degradation protein products of the RAS and the KKS are antiangiogenic whereas 
intact proteins and defined biologically active peptides are proangiogenic.  
 
Figure 1.4: Interactions of the RAS and the KKS. HMWK; high molecular weight kininogen; 
HMWKa, plasma cleaved high molecular weight kininogen; PK, plasma kallikrein; PRCP, 
prolylcarboxypeptidase;  ACE, angiotensin converting enzyme; ACE2, angiotensin converting 
enzyme 2; TF, tissue factor; PAI-1, plasmonogen activator inhibitor 1; tPA, tissue 
plasminogen activator; NO, nitric oxide; PGI2, prostacyclin; AT1R, angiotensin type 1 
receptor; AT2R, angiotensin type 2 receptor; BKR-2, bradykinin type 2 receptor. Adapted 
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1.4 Clinical Indications of ACEi 
 Inhibition of ACE by ACEi impacts on both the RAAS and the KKS. Circulating AngII is 
potent regulator of blood pressure and inhibition of the RAAS results in a fall in blood 
pressure [84]. Captopril was the first ACEi introduced in 1981 with other ACEi enalapril and 
lisinopril being approved later. Currently there about 17 ACEi approved for clinical use. 
ACEi are recommended for the treatment of hypertension, especially in the presence of left 
ventricular hypertrophy and congestive heart failure [85-87]. Together with aspirin, "-
adrenergic antagonists and statins, ACEi are now considered to be routine therapy to prevent 
secondary cardiovascular diseases due to their long-acting protective cardiovascular 
effects[88-90]. According to the American Heart Association, the prevalence of heart failure 
in the United State is estimated to be 2.2%. Patients with congestive heart failure (CHF) that 
were stabilized with diuretics should be further considered for ACEi therapy, unless there are 
specific contraindications (such as aortic stenosis) [91]. Moreover, ACEi slow the 
progression of atherosclerotic vascular disease, a benefit attributed to their direct vascular 
protective and anti-atherogenic effects.  In addition to their antihypertensive and 
cardiovascular protective effects, ACEi have shown renal protective effects [92].  
Many individuals with hypertension or CHF are insulin resistant and at the higher risk of 
developing type II diabetes mellitus. A meta-analysis of a randomized controlled trials has 
shown that ACEi consistently and significantly reduced the incidence of type II diabetes 
mellitus in individuals with hypertension or CHF and prevents the progression to 
nephropathy [93]. This antiproteinuric effect is independent of changes in blood pressure 
[94]. In patients with type I diabetes mellitus ACEi have been shown to prevent diabetic 
nephropathy [95]. Other beneficial effects of ACEi therapy include antithrombosis, increased 
adiponectin levels and increased insulin sensitivity[96-98]. Furthermore ACEi also mediate 
angiogenesis. ACE inhibition results in delays in postichemic reparative process and increase 
vessel density and capillary numbers.  Many of the beneficial effects of ACEi are to the 
inhibition of BK breakdown and are mainly mediated through the BKR-2. However increased 
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have also been shown to have be antiproliferative and antifibrotic effects[99]. A rat model 
study revealed that N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a natural inhibitor of 
hematopoietic stem cell proliferation and natural substrate of ACE, inhibited rat cardiac 
fibroblast proliferation and collagen synthesis and mesangial cell proliferation[100]. Ac-SDKP 
also prevents left ventricular and renal fibrosis in hypertensive rats. Thus the antifibrotic and 
antiproliferative of ACEi are mediated by preventing endogenous Ac-SDKP degradation, 
thereby increaseing plasma and tissue Ac-SDKP levels[99;99]. Furthermore increased Ac-
SDKP levels suppress cardiac collagen deposition by decreasing both expression of 
transforming growth factor-" and Smad2 phosphorylation, which are essential for collagen 
synthesis[100]. It is noteworthy that antifibrotic effects of ACEi in angiotensin II induced 
hypertension are not associated with hemodynamic changes.  
 
  Figure 1.5:  Detrimental and beneficial effects of bradykinin via its type 2 receptor. BKR-2, 
bradykinin type receptor; PGH2, prostaglandin; NO, nitric oxide; PGI2, prostacyclin; EDHF, 
epithelial dihyperpolarizing factor.  Adapted from Bas et al 2010 
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1.5 Clinical Presentation of ACEi Associated AE 
Angioedema (AE) is characterized by self-limited, nonpitting edema of vascular origin. The 
most common sites of ACEi-AE are the lips, tongue and face [101-103] (figure 1.6). 
Involvement of the glottis obstructs the airway and causes death by asphyxiation.  Rarely 
ACEi-AE may involve the bowel wall [104;105] and patients present with nausea, vomiting, 
abdominal pain, diarrhea or ascites. In such cases, diagnosis may be confirmed by the 
identification of bowel edema on CT scan. Discontinuation of ACEi is used to resolve 
symptoms, although failure to suspect ACEi-AE might necessitate surgical intervention 
(fig1.5b). ACEi-AE incidence is highest during the first month of treatment [2].  A 14-fold 
increase of AE during the first week of treatment compared with subsequent exposure was 
observed in one study, and another study observed a 9 fold incidence of AE during the first 
month of ACEi use. Although the risk of AE per exposure is greatest in the first month of 
treatment with ACEi, the majority of cases occur after 1 month of treatment with as many as 
27% cases reported after more than six months occurring after initiation of ACEi therapy 
[105;106]. AE onset in one series ranged from 1 day to 10 years of treatment [107]. Early 
recognition and discontinuation of ACEi remains a primary therapy for ACEi-AE [2]. 
However, it has been reported that administering complement 1 esterase inhibitor (CINH) 
concentrate decreased symptoms of AE in a patient who had ACEi-AE [108]. Also, the 
kallikrein inhibitor ecallantide, which was approved by the FDA in 2009 [109]. 















 Figure 1.6: A patient with swollen upper and bottom lip. B patient with more severe 
angioedema and patient had to undergo tracheostomy. Pictures taken at Victoria Hospital 
Wynberg, Cape Town by Dr Clint Cupido.  
 
1.6 Other Forms of Angioedema 
Hereditary angioedema (HAE) is a rare autosomal dominant disorder characterised by 
recurrent attacks of AE as a result of CINH deficiency[111]. It consists of three variants 
namely type I (HAE-I), type II (HAE-II) and type III (HAE-II)[112-114]. HAE-I and HAE-
II occur as a result of mutations in the C1 inhibitor gene located on q12-q13.1 in the subregion 
of chromosome 11[115]. Mutations result in either no activity of CINH (HAE-I) or 
dysfunctional CINH (HAE-II)[115;116]. The complement system is composed of 20 
proteins that circulate as inactive precursors. Classical or alternative activation of this system 
results in opsonization, lysis, chemotaxis, histamine release and immune complex clearance.  
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the classical pathway is composed of three subunits C1q, C1r and C1s. C1 binds to 
immunoglobin-bound to antigens triggering activation of other components of the cascade. 
CINH normally limits the amount of complement activation, however in HAE-I and HAE-II 
due to CINH deficiency the complement system is activated leading to release of biologically 
active peptides such as bradykinin.    This results in increased vascular permeability and 
edema of the airway, trunk, limbs, genital tract and gastrointestinal tract.  Both types of HAE 
are associated with low C4 levels and normal levels of C3. C1q levels are also normal except 
during AE attacks[117].  HAE-I is composed of approximately 85% of CIHN-associated 
HAE cases characterised by defective expression of 1 allele leading to both low antigenic and 
functional C1-INH[118].  On the other hand HAE-II comprises 15 % of all CINH-associated 
HAE cases[118]. It is characterised by functionally low C1-INH levels with either increased 
or normal C1-INH antigenic levels with the presence of a dysfunctional mutant protein. For 
both HAE types, C1-INH is usually 5-30% of the normal instead of the 50% expected if the 
single allele was fully expressed. Thus the difference leads to permanent C1 and contact phase 
activation subsequently leading to peripheral C1-INH consumption[119;120]. 
 Type III HAE (HAE-III) manifests only in women and its symptoms resemble those of 
CINH-associated HAE, but occurs in the presence of normal C1-INH levels[121]. It is 
associated with increased levels of estrogen. It has been reported that HAE-III is associated 
with the gain of function mutation in the gene encoding fXII[122]. The Thr328Lys substation 
in exon 9 results in increased fXII activity but not protein levels[122]. Earlier studies showed 
that an estrogen response element in promoter of fXII gene leads to increased gene expression 
during increased estrogen states[121]. Thus both increased estrogen levels and Thr328Lys 
substitution leads to high fXII activity resulting in increased BK production.      
Acquired AE (AAE) usually  results from lymphoproliferative disorders, autoimmune 
responses, neoplastic  and infectious diseases[123]. AAE is characterised by low functional 
C1-INH, low C4 levels and normal C3 levels. Contrast to HAE, AAE is also characterised by 











          Chapter 1 2011 
Literature Review 
 18 
1.7 Epidemiology of ACEi Associated AE 
The reported incidence of ACEi-AE varies from 0.1-0.7%, calculated from post-marketing 
surveillance or epidemiologic studies, to as great as 2.8-6.0% when ascertained prospectively 
in clinical trials [103;106;125]. Black Americans have increased incidence of ACEi-associated 
AE that is 4-5 times more that of white Americans[106;125;126]. In Cape Town black and 
coloured South Africans, the incidence of ACEi-associated AE has also been reported to be 
high [127]. A history of ACEi-cough increases the risk of AE [128]. Nevertheless, patterns of 
racial differences in the incidence of ACEi-induced cough and ACEi-AE do not suggest a tight 
link between cough and AE. These are exemplified by the frequent development of cough in 
Asian patients who are not at an increased risk of AE [128;129]. Furthermore, a high 
prevalence of cough has been observed in the South African Indian Durban population on 
ACEi perindopril and no reported ACEi-AE [130]. 
 
1.8 Pathophysiological Mechanism of ACEi Associated AE 
The pathophysiology of ACEi-AE remains to be elucidated. Nonetheless, it appears to be a 
biochemically, rather than immunologically mediated phenomenon [131].  ACE inactivates a 
potent vasodilator BK and converts AngI to a potent vasoconstrictor AngII.  The action of 
ACEi depends mainly on blocking ACE in RAS to decrease AngII production and cause 
vasodilation by increased BK levels in the KKS. The long term benefit of ACEi in patients 
with heart failure results from increased plasma BK half-life [132]. Hence it has been 
suggested that BK accumulates in patients on ACEi because of the inhibition of ACE 
responsible for its metabolism[133;134]. This causes vasodilation and edema in susceptible 
individuals[135]. ACEi increase circulating levels of BK and  also local levels of BK 
responsible for vasodilation[136]. This explains why local swelling in ACEi related AE is 
triggered by minor trauma and not generalized swelling. Trauma may also activate the KKS 
leading to AE. The levels of CINH, C4 and IgE are normal in ACEi-AE patients. 
Additionally, half of the patients presenting with ACEi-AE may also have a defect in the 
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been suggested that an enzyme defect rather than circulating inhibitor could be responsible for 
abnormal metabolism of des-Arg9BK when ACE is inhibited. Abnormal endogenous des-
Arg9BK degradation was found in plasma of patients presenting with ACEi-AE[138]. This 
evidence suggests that one possible pathogenic mechanism of AE lies in the catabolic site of 
kinin metabolism. Although less frequent, occurrence of AE due to angiotensin type II 
receptor blockers (ARBs) suggests that BK is not the only mechanism involved in ACEi 
induced AE. Whilst the levels of CINH are usually normal in ACEi-AE patients, it has been 
found that ACEi caused AE in CINH deficient subjects[139]. Furthermore ACEi lead to 
resensitization of BKR-2, further compounding to ACEi-AE pathophysiology in susceptible 
individuals.  ACEi-AE is also associated with increased plasma concentrations of acute phase 
proteins fibrinogen and C-reactive protein suggesting that these acute phase reactants might 
be involved in the pathogenesis of ACEi-AE[140;141]. Interestingly, the levels of these acute 
phase proteins returned to normal after ACEi discontinuation and AE resolution. 
Furthermore, the levels of these proteins were normal in patients treated with ACEi who had 
no AE. This result suggests a contribution of the inflammatory process in the 
pathophysiology of AE.   However, it remains to be seen as whether or not acute phase 
proteins are truly triggering AE attacks. 
 
1.9 Aminopeptidase P Deficiency and Adverse Events Associated With ACE Inhibition 
APP degradation of BK increases during ACE inhibition[142;143]. Thus during ACE 
inhibition, deficient APP activity leads to enhanced conversion of kallidin by PK and BK by 
CPN thus leading to accumulation of BK and des-Arg9BK[2]. Adam et al reported a 30% 
decreased activity in serum APP in  39 patients that had a history of ACEi-AE compared to 
39 hypertensive controls[144]. Furthermore metabolism of BK and des-Arg9BK was 
characterized following stimulation of formation with ex vivo incubation of plasma with glass 
beads[145]. In the presence of ACEi (enalapril 130nM), the investigators showed a slight but 
significant (P=0.022) decrease in catabolism of BK in patients who had a history of AE.  
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(AUC) in AE patients versus controls. In contrast, both maximal des-Arg9BK and the AUC 
for des Arg9BK were significantly increased in AE patients as well as the half-life of 
degradation. These data confirm increased formation of des-Arg9 by CPN in sera of patients 
who had AE raising the possibility of decreased degradation of this peptide. Decreased APP 
activity does not account entirely for the pathophysiology of ACEi-AE despite this 
interesting data. This is because one third of individuals who had ACEi induced AE had 
normal levels of APP. Additionally, the occurrence of decreased APP activity in the 
population (18%) is much more than that of angioedema due to ACEi. Furthermore, decreased 
APP activity or des-Arg9BK metabolism in black patients with a history of ACEi-AE has not 
been investigated.  Taken together, these data suggests that other pathways other than APP 
play a role in ACEi- AE. 
 
1.10 Pharmacogenetics of ACEi Induced AE 
Contrary to hereditary angioedema, in which mutations in the CINH have been identified no 
specific mutations in ACEi-AE have been identified. However, an ethnic difference in the 
occurrence of AE provides some presumptive clues that genetic factors play a role. Research 
has  primarily focused on enzymes involved in the degradation of BK. Based on the data that 
APP activity is reduced in patients with ACEi-AE, Duan et al performed a quantitative trait 
locus analysis to determine the genetic factors regulating APP activity in eight pedigrees in 
which at least one family member had developed an anaphylactoid reaction during 
hemodialysis (six families), AE (one family) or both (one family)[12]. Human APP exists in 
two forms, a glycosylphosphatidylinositol (GPI) anchored membrane form (hmAPP) 
encoded by XPNPEP2 gene and a cytosolic form (hcAPP) encoded by XPNPEPL gene. The 
gene encoding for hmAPP is localized on chromosome Xq26.1 whereas hcAPP gene is located 
on 10q25.1. Investigators found that variation in XPNPEP2 gene accounted for 34% of the 
heritability of plasma APP activity[12]. No linkage was found with hcAPP gene suggesting 
that it is hmAPP that primarily contributes to plasma APP activity. Interestingly the 
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plasma APP activity, such that the A allele was associated with lower APP activity.  
Moreover, in white unrelated ACEi associated cases and controls, an association between C-
2399A genotype and APP was confirmed. Additionally the investigators identified a 175bp 
genomic deletion (g.2953-3127) that resulted in a truncated protein in one family with a 
proband of both AE and anaphylactoid reaction. The mutant transcript lacked both predicted 
sites and the GPI anchor. Although interesting, this finding that variation in gene encoding for 
hmAPP predicted APP activity in families with a history of anaphylactoid reactions, the 
applicability of these findings to those who are at risk for ACEi-AE is uncertain. 
Hypotension is typical characteristic of patients who have anaphylactoid reactions and AE; 
however it is not a feature of ACEi-AE. In addition, mutations in an X-linked gene are not 
likely to account for the majority of ACEi-AE as ACEi- AE affects more women than men. 
The ACE gene is located on chromosome 17 in humans and the polymorphism is detected in 
intron 16 based on the insertion/deletion (I/D) of 287 bp. The average serum levels of DD 
genotype are higher than that of ACE-II genotype [146]. Polymorphisms in the ACE gene 
have been shown to correlate with hypertension[147], physical performance[148], left 
ventricular hypertrophy [149] and diabetic nephropathy[150] in different societies. The role 
of ACE gene polymorphism in Caucasians was proven to have no effect in ACEi or ARB 
induced angioedema subjects [146]. 
The BKR-2 has high affinity for both BK and kallidin, but not other BK metabolites. BK 
vasodilation is mediated primarily through these receptors.  The +9/+9 genotype of BKR-2  
+9/-9 exon 1 polymorphism has been shown to be associated with decreased vasodilation and 
tPA production in response to BK during ACE inhibition compared with -9/-9 allele[151]. 
Furthermore, the -9/-9 allele has been associated with increased severity of AE in cases of 
HAE-I[152]. Interestingly, the C-58T BKR-2 promoter polymorphism has been associated 
with increased risk of essential hypertension in African Americans and also with ACEi-cough 
in Chinese patients[153;154]. However both +9/-9 and C-58T have never been investigated 















Given that most studies were conducted elsewhere, it was hypothesized that genetic 
polymorphisms and biochemical mechanisms play a key role in ACEi induced-AE in black 
and coloured South Africans.  
Aim and Objectives of this Study 
The aim of the study was to investigate whether the correlation between serum ACE and 
mAPP activity activities are associated with C-2399A SNP in the XPNPEP2 gene and ACE 
I/D polymorphism in the ACE gene in ACEi induced cough and ACEi associated-AE 
patients. Furthermore the roles of BKR-2 +9/-9 and -C58T polymorphisms in ACEi-AE and 
ACEi-cough patients were investigated.  To achieve these, the following objectives were 
established: 
1. Recruiting controls (patients on treatment with ACEi but free of side effects), ACEi-
AE patients as well as  ACEi induced cough patients  
2. PCR amplification and analysis of ACE I/D polymorphism; XPNPEP2 gene C2399A 
SNP; BKR-2 +9/-9 and C-58T polymorphisms and determination of their association 
with ACEi-AE and ACEi-cough. 
3. Analysing serum ACE activity in controls, cough and AE patients and determine the 
significance in levels between the three cohorts 
4. Serum APP activity determination in controls, ACEi-AE and ACEi induced cough 
patients and show whether there is a significant difference in APP levels between the 
three cohorts 
5. Correlating between activities and genotypic data in all three cohorts and show 
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2.1 Participants Recruitment 
All cohorts were recruited at the Hypertension Clinic at Groote Schuur Hospital and Victoria 
Hospital Wynberg. Three different cohorts were recruited as part of the study. Cohort 1 was 
composed of hypertensive patients currently on treatment with ACEi enalapril for more than 
two years and with no apparent side effects. These participants were used as controls for the 
study. These participants were also asked to provide details of the dosage of ACEi. Cohort 2 
was patients that previously had or presented to the hospital with ACEi-AE. Cohort 3 was 
composed of patients who had previously presented/reported to the hospital with ACEi-
cough whilst on treatment and were subsequently discontinued from ACEi. All participants 
underwent preparation to explain explicitly the rationale and significance of the study.  Once 
a participant agreed to be part of the study, a questionnaire (Appendix I) was then filled with 
participant details such as name; hospital no; age; gender and race. Participants were also 
asked to provide whether they currently smoked or had a history of smoking. Seasonal 
allergies and co-morbidities such as diabetes, congestive heart failure and kidney failure were 
also recorded.  All participants were requested to give details of other antihypertensive drugs 
they were taking.  The date of the episode, frequency, localization and severity of AE were 
recorded. AE was then divided in to three categories depending on the severity as follows: 
Mild: Patients presenting with AE and ACEi being discontinued and the swelling returning to 
normal after 2-3 hours. 
Moderate:   Patients presenting with massive swelling, ACEi discontinuation and 
antihistamine or adrenalin administration to reduce the swelling. 
Severe: Patients presenting with massive swelling, airway obstruction and hospitalized 
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2.2 Sample Collection and Processing 
All selected participants were requested to donate blood samples after completing the 
questionnaire and DNA ethics forms respectively.  For controls, samples were taken when 
they were taking enalapril and when they were not taking enalapril for 48 hours.  5 milliliters 
(ml) of venous blood was collected from each participant by venipuncture of a forearm vein 
into each of EDTA, serum separator (SST) and heparin Vacutainer tubes. The tubes were 
immediately mixed by inversion to ensure adequate mixing with the anticoagulant. Heparin 
tubes were immediately placed on ice and EDTA and SST were kept at room temperature 
until centrifugation. For serum, SST tubes were centrifuged at 3000rpm for 10 min at 4oC and 
within 30 min of centrifugation aliquots of the supernatant were transferred into pre-labeled 
eppendorf tubes and stored at -80oC until further analysis.  For DNA, EDTA tubes were 
centrifuged at 3000rpm at 4oC for 10 min. Then the buffy coat (white layer between red 
blood cells and plasma) was extracted and transferred into pre-labeled eppendorf tubes and 
stored at -20oC until further analysis. The buffy coat contains lymphocytes that are rich in 
DNA. For plasma, the heparin tubes were centrifuged at 3000rpm at 4oC for 10min and the 
supernatant was transferred into pre-labeled eppendorf tubes and aliquots placed on ice 
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2.3 Summary 
Participants’ characteristics are shown in Table 1. A total of 165 participants were enrolled 
as part of the study. In cohort 1, a total of 77 participants were enrolled with coloureds being 
the majority with 71.4% compared to 25.9% blacks and 2.7% whites. There were more 
females (57.2%) than males (42.8%) in this cohort. The majority were non-diabetic with 
70.1% versus 29.9% diabetics. All participants in cohort 1 were on treatment with 10mg 
ACEi enalapril taken twice daily specifically in the mornings and the evenings for more than 2 
years and were free of ACEi side effects.  With regards to cohort 2, a total 52 patients were 
recruited. Similarly, the majority were coloureds with 61.5% compared to 32.6% blacks and 
5.9% whites. Also females were the majority with 89% compared to 11% males and a large 
amount were non-diabetics with 54% compared to 46% diabetics. With respect to cohort 3, a 
total of 36 patients were enrolled.   Similar to both cohort 1 and 2, coloureds comprised the 
majority with 72% compared to 14% each of both blacks and whites. There were also more 
females (78.8%) than males (21.2%) and also more non-diabetics (75%) than diabetics (25%). 
Enalapril an ACEi was the causative agent of both ACEi-AE and ACEi-cough. The time of 
onset of angioedema after drug introduction varied from 1 month to 10 years. All cohorts 
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Table 1: Participants Characteristics 







Race n(%) n(%) n(%) 
Coloureds: 55(71.4) 32(61.5) 27(72) 
Blacks: 20(25.9) 17(32.6) 5(14) 
Whites: 2(2.7) 3(5.9) 5(14) 
Gender    
Male: 33(42.8) 4(11) 11(21.2) 
Female: 44(57.2) 33(89) 41(78.8) 
Comorbidities    
Diabetic: 23(29.9) 17(46) 13(25) 
Non-Diabetic: 54(70.1) 20(54) 39(75) 
 
AE was graded as mild, moderate and severe (See Table 2).  A large amount of patients had 
mild AE (57.6%) with the common sites of AE being the lips, tongue and face. Similar to 
earlier observations, coloureds comprised the majority of the mild cases with 60% with blacks 
and whites comprising of 37% and 3% respectively. There also were more females (76.7%) 
than males (23.3%) in mild AE cases. Moderate AE patients constituted 13.5% of all AE 
cases. Similarly, coloureds made-up the majority of moderate AE cases with 57% compared 
to 29% blacks and 14% whites. There also were more females (57.2%) than males (42.8%) 
with moderate AE. Severe AE patients made up 28.9% of all AE cases.  There were also more 
coloureds (67%) than blacks (27%) and whites (6%) in severe AE cases as with the mild and 
the moderate cases. There were also more females (93.3%) than males (6.7%) with severe AE. 
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Race n(%) n(%) n(%) 
Coloureds: 18(60) 4(57) 10(67) 
Blacks: 11(37) 2(29) 4(27) 
Whites: 1(3) 1(14) 1(6) 
Gender    
Male: 7(23.3) 3(42.8) 1(6.7) 
Female: 23(76.7) 4(57.2) 14(93.3) 
 
Table 3 presents the most common additional antihypertensive medications concomitantly 
used by all participants in the study. Diuretics were used by 80.5% controls; 82.7% ACEi-
AE patients and 75% ACEi-cough patients. Hydrochlorothiazide was the most commonly 
used diuretic. Calcium channel blockers (CCB) were used by 84.4% controls; 63.5% ACEi-
AE patients and 94.4% ACEi-cough patients. Amlodipine was the most commonly used 
CCB. ! adrenergic receptor blocker Atenolol was taken by 67.5% controls; 34.6 ACEi-AE 
patients and 63.8% ACEi-cough patients. Cardura, an " adrenergic Blocker, was taken by 
18.2% controls; 3.8 ACEi-AE patients and 13.8% ACEi-cough patients. Combined " ! 
adrenergic receptor blocker Carvedilol used by 5.2% controls and 1.9% ACEi-AE patients. 
Potassium sparing diuretics were used by 25.9% controls; 9.6% ACEi-AE patients and 
27.7% ACEi-cough patients. Spironolactone was the most commonly used.  Hyralazine, a 
direct-acting smooth muscle relaxant was used by 36.4 % of controls; 11.5% ACEi-AE 
patients and 25% ACEi-cough patients. Angiotensin receptor blocker (ARB) Telmisartan was 
used by about 13.5% ACEi-AE patients and 19.4% ACEi-cough. These patients did not 
develop AE and cough associated with ARB use. Lastly simvastatin, a cholesterol lowering 
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Table 3: Other Antihypertensive Medications  






 Cohort 3 (ACEi-
Cough) 
n=36 
Drug n(%) n(%) n(%) 
Diuretics (Hydrochlorothiazide, 
Furosimide) 
62(80.5) 43(82.7) 27(75) 
Calcium Channel Blockers  
(Verapimil, Amlodipine) 
65(84.4) 33(63.5) 34(94.4) 
!Adrenergic Receptor  Blockers 
( Atenolol) 
52(67.5) 18(34.6) 23(63.8) 
"Adrenergic Receptor Blockers 
(Cardura) 
14(18.2) 2(3.8) 5(13.8) 
Combined Adrenergic Receptor 
Blockers (Carvedilol) 
4(5.2) 1(1.9) ------------- 
Potassium Sparing Diuretics ( 
Spironolactone, Amiloride) 
20(25.9) 5(9.6) 10(27.7) 
Hydralazine 28(36.4) 6(11.5) 9(25) 
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2.5 Samples 
DNA samples were collected from all 165 participants in the study. The total serum and 
plasma sample collected was 117. Serum and Plasma samples were collected from 29 controls 
when they were taking enalapril and not taking enalapril. The difficulty was getting samples 
from the rest of the control participants when they were not taking enalapril as they did not 
come back to the hospital after the specified time period. Serum and plasma samples were 
collected from 52 ACEi-AE and 36 ACEi-cough patients.  . 
2.5 Ethics Approval 
The study protocol was approved by the University of Cape Town Human Research Ethics 
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Genetic Polymorphism is defined as the difference in DNA sequence among individuals, 
groups, or populations. Sources include single nucleotide polymorphisms, sequence repeats, 
insertions, deletions and recombination. (e.g. a genetic polymorphism might give rise to blue 
eyes versus brown eyes, or straight hair versus curly hair). Genetic polymorphisms may be 
the result of evolutionary processes, or may have been induced by external agents such as 
viruses or radiation. If a difference in DNA sequence among individuals has been shown to be 
associated with disease, it will usually be called a genetic mutation. Thus genetic differences 
between individuals can be used to study differences in drug responses to determine the 
therapeutic effect as well as adverse side effects. The ACE I/D and the BKR-  
+9/-9 polymorphisms and the XPNPEP2 C-2399A and the BKR-2 SNPs have been 
associated with ACEi side effects in other populations. 
Aim: To investigate the importance of known genetic polymorphisms in the XPNPEP2, 
ACE, and BKR-2 genes respectively in ACEi associated AE and ACEi induced cough 
patients in black and coloured South Africans.  
The objectives of the present work were therefore to: 
1. To investigate the role of ACEI/D polymorphism in ACEi-AE and ACEi -cough 
patients  
2. To assess the association of C-2399A single nucleotide polymorphism (SNP) with 
ACEi-AE and ACEi-cough 
3. To evaluate the role of BKR-2 9bp insertion/deletion polymorphism in ACEi-AE and 
ACEi-AE patients 
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3.2.1 DNA Extraction 
Extraction of DNA was performed using QIAGEN QIAamp® DNA Blood Mini Kit (250) 
according to the manufacturer’s instructions.  
The QIAamp DNA purification procedure comprises of four steps and was carried using the 
QIAamp Spin Column in a standard microcentrifuge. The spin column procedure ensures that 
there is no sample-to-sample cross contamination and allow for safe handling of potentially 
infectious samples. 
Twenty microlitres of QIAGEN Protease® or Proteinase K was pipetted into a 1.5ml micro-
centrifuge tube and 200!l of patient’s sample (buffy coat) was added. Protease or Proteinase 
K serves the function of degrading cellular proteins such as Histones. Smaller sample volumes 
were adjusted to 200!l final volume with PBS before loading. Then 200!l AL buffer was 
added to remove lipid membranes and disrupt the cell membrane and the nuclear envelope 
causing cells to burst open and release DNA.  The mixture was mixed by pulse-vortexing for 
15sec. The mixture was then incubated at 56oC for 2hours. 200!l ethanol was added to the 
mixture and pulse-vortex for 15sec to mix. The mixture was carefully added to a spin column 
placed in a 2ml collection tube and centrifuged at 13000rpm for 1min. The column was placed 
into another clean collection tube and the tube containing the resulting filtrate was discarded. 
500!l AW1 buffer was added to the column and centrifuged for 1min. The column was then 
placed into a clean collection tube and collection tube containing the filtrate was discarded.  
To the column, 500!l of AW2 was added and centrifuged for 3min. After centrifugation the 
tube containing the filtrate was discarded and the column was placed on a clean eppendorf 
tube marked with the patient number.  Finally 200!l TE buffer was added to the column, 
incubated at room temperature 1-5min to increase DNA yield and thereafter centrifuged for 
1min. The DNA concentration in the tube was determined using a nano drop 
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3.2.2 PCR Amplification of the ACE Insertion/Deletion Polymorphism 
 PCR was employed to amplify the deletion (D) or insertion (I) allele fragments from intron 
16 of the ACE gene located on chromosome 17. Readily available software Oligo®, was used 
to design primers. Primer pairs were checked for length, compatible melting temperatures and 
possible primer dimers. The primer pair was the blasted in using NCBI blast software to 
ensure primer specificity.  Figure 3.1 presents primer pair used for the analysis. 








                                                                                                               Reverse Primer 
Figure 3.1 Primer positions on the intron 16 of the ACE gene. The 287bp insertion or 
deletion sequence is indicated by red coloured sequence. 
The PCR reaction was performed in total volume of 15!l. The PCR reagent contained 
premixed master mix consisting of:  0.6µl 5mM dNTP with a final concentration of 0.2mM; 
3µl 5x Green Go Taq® (Promega) flexi buffer pH 8.5 with a final concentration of 1x buffer; 
0.9µl 5mM MgCl2 at the final concentration of 1.5mM; 8.525µl nuclease free water; 0.15µl of 
50pmol final concentration 0.01pmol of both the forward and reverse primers; 0.075µl Go 
Taq flexi DNA polymerase 5U/µl with a final concentration of 1U.   The presence of the 
ACE I/D was amplified by adding 1µl DNA from each specimen to the mix. The 
amplification was performed using the GeneAmp® PCR System 2700 (Applied Biosystems). 
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annealing at 65oC for 30sec and 45sec at 72oC for DNA extension.  After the cycle, the 
reaction was completed at 72oC for 8min. The PCR products were then separated using 2% 
agarose gel run for 30 minutes at 120V and 250mA. The agarose gel was made up using 
commercially available agarose (LE, analytical grade, Promega) mixed in 1x Tris-acetate-
EDTA buffer to make 2% gel solution. The agarose was dissolved by heating in the 
microwave and 5µl of 10mg/ml ethidium bromide was added before being set. After 
electrophoresis the flourChem 500 transilluminator was used to visualize I and D alleles 
(figure 3.2).  
 
Figure 3.2 2% agarose gel after electrophoresis confirming the PCR product of the ACE I/D 
polymorphism. The presence of the ACE-I allele is indicated by a 607bp product whereas the 
ACE-D allele is indicated by a 320bp product. A negative control confirmed no contamination 
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3.2.3 XPNPEP2 Gene C-2399A SNP Detection 
The C-2399 (-2399A C>A, rs3788853) SNP in the promoter region of the XPNPEP2 gene 
was genotyped using allele specific primers described elsewhere (152). Oligonucleotides for 
PCR were designed from the genomic sequences for the human XPNPEP2 gene. This required 
three PCR primers for each polymorphic site. The allele specific primers differed at the 
position of the 3’-most nucleotide. Two standard PCRs were performed using common 
primer (Pr.F 5’-AACCTCCCCACGTTGAATCA-3’) and either one of the allele-specific 
primers (Pr.R A 5’GCACTGCTGAAATAGCAGTTGTTAT-3’) or (Pr.R C 5’-
GCACTGCTGAAATAGCAGTTGTTAG-3’).  
The total reaction volume for PCR was 15!l. The PCR reagent contained: 2µl 5mM dNTPS 
at final concentration of 0.2mM; 1.5µl 10X Taq buffer at final concentration of 1X; 0.3µl 
5mM MgCl2 at the final concentration of 1.5mM; 10.375µl nuclease free water; 0.15µl 50µM 
at the final concentration of 0.5µM each of the common, forward and reverse primers; 0.15µl 
50µM at the final concentration of 0.5µM of the forward and reverse cystinosis gene primers. 
The cystinosis gene primers were included to check whether DNA has been added to the PCR 
tube and used as control and finally 0.075µl of 5U/µl Super Therm Gold DNA Taq 
polymerase with a final concentration of 1U was also added premixed master mix. The 
C2399A SNP was amplified by adding 1µl of each patient sample to the total reaction 
mixture. The GeneAmp® PCR System 2700 (Applied Biosystems) was used for 
amplification.  The amplification program was set at the initial step of denaturation step of 
95oC for 10min for 1 cycle, followed by 30sec of denaturation at 95oC for 30 cycles, 
annealing at 65 for 30sec and 50sec at 72oC for DNA extension, followed by final extension of 
1 cycle for 8min. The PCR products were then separated using 2% agarose gel and A or C 
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Figure 3.3 Represents 2% agarose gel after electrophoresis of the C-2399A SNP in the 
XPNPEP2 gene. The presence of the PCR product for the cystinosis gene housekeeping 
control is confirmed by 681bp band/s. The presence of C-2339A SNP is demonstrated by 351 
bp band.    
 
3.2.4 BKR-2 +9/-9 bp Insertion/Deletion P lymorphism PCR Detection 
The non-coding exon 1 9 bp insertion (+9) or deletion (-9) (rs71103505, ggtggggac/-) BKR-2 
polymorphism located on chromosome14q32.1-q32.2 was determined and amplified using 
PCR. Readily available software Oligo®, was used to design primers. The primers were 
checked for length, compatible melting temperatures and possible primer dimers. The primer 
pair was also blasted using NCBI primer blast software to check that the primer pair binds to 
the BKR-2 +9/-9 region and not in any other region in the human genome. The primer pair 
used for PCR detection is presented on figure 3.4. 
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    Forward Primer 
ctgttcccgccgccactctggcttctgggctccgaggaggggtggggacggtggggacggtggggacat 
                                                                                                                         +9/-9 band                                      
caggctgccccgcagtaccagggagcgactgaagtgcccatgccgct 
                                                                    Reverse Primer 
                                                         
Figure 3.4 Primer position on the BKR-2 exon 1 +9/-9                                        
The PCR reaction was performed in a total reaction volume of 15!l. The PCR reagent 
consisted of: 0.6µl 5mM dNTPS with a final concentration of 0.2mM; 1.5µl 10X Taq buffer 
with a final concentration of 1X; 0.18µl 25mM MgCl2 with a final concentration of 0.03mM; 
11.95µl nuclease free water; 0.15µl 50µM with a final concentration of 0.5µM of both the 
forward and reverse primers and 0.075µl of 5U/µl Super Therm Gold DNA Taq polymerase 
with a final concentration of 1U. The BKR-2 +9/-9 bp was amplified by adding 1µl DNA of 
each patient to the PCR mix. The amplification was performed using the GeneAmp® PCR 
System 2700 (Applied Biosystems). The amplification program consisted of the initial 
denaturation step of 95oC for 10min, followed by 30sec of denaturation at 95oC for 30 cycles, 
annealing at 60.6 for 30sec and 30sec at 72oC for DNA extension, followed by final extension 
of 1 cycle for 8min. The PCR products were then separated on 7.5% polyacrylamide gel run 
for 60 minutes at 250V and 500mA. The polyacrylamide gel was made up using commercially 
available 30% Acrylamide/Bis (Bio-Rad Laboratories Inc) mixed in 10x Tris-Borate-EDTA 
buffer, 10% AMPS and 1% TEMED to  make 7.5% gel solution. After electrophoresis 
polyacrylamide gel was immersed in ethidium bromide solution and the flourChem 500 
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3.5 Demonstrates 7.5 %Polyacrylamide gel confirming the PCR product of the BKR-2 +9/-9 
polymorphism. The presence of the +9/-9 is confirmed by the presence of 102 and 93bp 
bands. Negative control confirmed no contamination in the reagents or primers.  
3.2.5 BKR-2 C-58T SNP PCR Detection 
The BKR-2 C-58T (-58C>T, rs1799722) SNP in the promoter region of the BKR-2 gene 
located on chromosome14q32.1-q32.2 was detected using PCR. Readily available software 
Oligo®, was used to design primers, check for length, compatible melting temperatures and 
possible primer dimers. The primers were then blasted using NCBI primer blast software to 
check for primer specificity. The primer pair used for PCR detection is presented on figure 
3.6. Because the C-58T substitution does not alter a recognition sequence for a restriction 
enzyme, a partial recognition site for TSP45I (Fermentas) was introduced by introduction of a 
single mismatch base in the forward primer (figure 3.6). 
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                                   Forward Primer 
aggcggaggggaagtgcccaggaggctgatgacgtcacCtacccagcccttgaa                            
agatgagctgttcccgccgccactccagctctggcttctgggctccgaggagggt  
                                                                                      Reverse Primer 
 
Figure 3.6 Primer position for BKR-2 C-58T (red). Forward primer had a single mismatch 
base (bold) to introduce a recognition site for TSP45I which is shown by the box. The C-58T 
SNP is indicated by the C. 
 
The PCR reaction was performed in total volume of 15!l The PCR mix contained: 0.6µl 
5mM dNTPS with a final concentration of 0.2mM; 1.5!l 10X Taq buffer with a final 
concentration of 1X; 0.18!l 25mM MgCl2 with a final concentration of 0.03mM; 11.95 
nuclease free water; 0.15!l 50!M made to a final concentration of 0.5!M of both the forward 
and reverse primers and 0.075!l 5U Super Therm Gold DNA Taq polymerase with a final 
concentration of 1U. The BKR-2 promoter C-58T SNP was amplified by adding 1µl DNA 
from each specimen. The amplification was performed using the G-STORM® PCR System 
(Vacutec). The amplification program consisted of the initial denaturation step of 95oC for 
10min, followed by 30sec of denaturation at 95oC for 30 cycles, annealing at 60.6 for 30sec 
and 30sec at 72oC for DNA extension, followed by final extension of 1 cycle for 8min. 
(fig3.5). 10µl of the PCR product was digested with restriction enzyme TSP45I overnight at 
37oC. TSP45I restriction is produced by Neisseria mucosa C9-2 and recognizes DNA 
sequences 5’GTSAC’3 and 3’CASTG’5 respectively (figure 3.6). The resulting products 
were then separated on a 4% agarose gel run for 40 minutes at 120V and 250mA. 4g of the 
agarose powder was dissolved in 100ml 1X TE buffer and 5µl of 10mg/ml ethidium bromide 
was added before being set. After electrophoresis the flourChem 500 transilluminator was 
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Figure 3.6 Presents 4% agarose gel after electrophoresis of the C-58T SNP after Restriction 
enzyme digestion with TSP45I. The presence of the T allele is confirmed by the presence of 
86bp band whereas the C allele is confirmed by PCR roduct of 66 and 20bp bands. The 
negative control confirmed no contamination in reagents or primers. The ACE-II was used as a 
positive control and the PCR product was confirmed by the presence of 310bp, 200bp and 
97bp bands respectively. 
Statistical Analysis  
The controls were tested for Hardy-Weinberg equilibrium (HWE) for all genotypes in this 
study. The Bonferroni correction test was done for all the genotypes and the P value of< 0.01 
was considered significant for analysis. The chi squared test was used to test for significance 
between cases and controls.  Statistical analysis was carried out using SPSS 18.0 (SPSS Inc., 
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3.2.1 ACE Insertion/Deletion Polymorphism Screen 
The role ACE I/D polymorphism was assessed in unrelated 165 South African hypertensive 
patients with or without a history of ACEi-AE or ACEi-cough (Table 4).  Genotypes were 
in the HWE (P=3.75) for all controls. The ACE I/D polymorphism displayed no significant 
difference overall between males and females (P=0.910) in the study. Amongst the South 
African blacks, coloureds and whites, no significant difference was shown in the study 
(P=0.087). Thus results are indicative of equal distribution of the I/D alleles in all patients. 
The ACE I/D polymorphism has been correlated with hypertension, physical performance, 
left ventricular hypertrophy and diabetic in different societies. Previous work has 
demonstrated ACEi-AE was higher in blacks and showed a link with the ACE-II genotype 
[155]. In another study no association was found between ACEi-AE and the ACE I/D 
polymorphism in Caucasians [146]. Since the majority of cases in the study with ACEi-AE 
and ACEi-cough were black and coloured South Africans, the role of ACE-II genotype was 
assessed.  The study exhibited no significant association of the ACE-II genotype with both 
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Table 4: ACE I/D Polymorphism Analysis 
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The relationship between ACE I/D polymorphism and ACEi-AE severity was sought (Table 
5). To my knowledge this has never been done previously. The results revealed significantly 
lower ACE-II genotype compared to ACE-ID and ACE-DD genotypes (P=0.01).  
Furthermore, no significant difference was found between males and females ACEi-AE cases 
with respect ACE I/D polymorphism (P=0.60). 
Table5: ACEi-AE Grades 
Characteristic II ID DD Total P Value 
ACEi-AE Grade n(%) n(%) n(%) n(%)  
Mild: 5(18.5) 12(33.3) 13(63.4) 30(100.00  
Moderate: 3(42.9) 2(28.5) 4(57.3) 7(100.0)  
Severe: 3(20.0) 8(53.3) 4(26.7) 15(100.0)  
Total 11(21.1) 20(38.5) 21(40.4) 52(100.0) 0.001 
Sex      
Male: 3(27.3) 5(45.4) 3(27.3) 11(100.0)  
Female: 8(19.5) 15(36.6) 18(43.9) 41(100.0)  
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3.2.2 Screening of the C-2399A SNP Associated Within the XPNPEP2 Gene  
To investigate the association of C-2399A SNP with ACEi-AE or ACEi-cough, DNA from 
165 unrelated South Africans with or without the histories of ACEi-AE or ACEi-cough was 
screened. The genotyping results of the C-2399A SNP with regards different South African 
ethnic groups are shown in Table 3.  The SNP revealed no significant difference between 
blacks, coloureds and whites (P=0.91).  It should be noted that whites had low sample size 
compared to other groups.   
Table 6 C2399A SNP Genotyping Results 
Characteristic A AC CC Total P Value 
Ethnicity n(%) n(%) n(%) n(%)  
Black: 9(22.5) 14(35.0) 17(42.5) 40(100.0)  
Coloured: 11(9.6) 36(31.3 68(59.1) 115(100)  
White: ------- 3(30) 7(70) 10(100)  
Total 20(12.1) 53(32.1) 92(55.8) 165(100.0) 0.91 
 
The relationship between C-2399A SNP was sought in males and females including ACEi-AE, 
and ACEi-cough (figure 3.7). Genotypes were in the HWE (P=0.72) among female controls. 
Figure 3.7A presents the association of C-2399A SNP in all males including patients and 
controls. The results revealed that males had lower -2399A (30%) allele frequency compared 
to -2399C allele (70%, P=0.0001). Females also had a lower -2399A (5.04%,) allele frequency 
compared to -2399AC (44.54%, P=0.0001) and  -2399C (50.42%, P=0.0001) (figure 3.7B). 
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all females (27%, P=0.64) (figure 3.7C). There was also no significant difference in -2399C 
allele frequency in males (70%) and females (73%, P=0.64). 
 
Figure 3.7 An Analysis of the C-2399A SNP in males. B Analysis of the C-2399A SNP in 
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The frequency of the C-2399A alleles was compared in ACE-AE and ACEi-cough patients 
against controls. Controls exhibited significantly higher -2399A allele frequency compared to 
ACEi- AE patients (21% vs 4%, P=0.01) (figure 3.8A). The -2399A allele was also 
significantly lower in ACEi-cough compared to controls (8% vs 21%, P=0.01) (figure 3.8A).  
This was surprising because the -2399A allele has been shown to be associated with 
decreased enzyme activity and associated with ACEi-AE (Duan 2004). However, due to low 
sample size, the association between C-2399A SNP and ACEi-AE and ACEi-cough cannot be 
discounted. There was no significant association with -2399AC allele with ACEi-AE patients 
compared to controls (36% vs 26%, P=0.31). Also no significant association was observed 
with -2399AC in ACEi-cough patients compared to controls (26% vs 36%, P=0.38). When 
the A allele was treated as a dominant (A+AC) no significant difference was observed between 
cases and controls (figure 3.8B). There was also no significant difference in C allele in both 
ACEi-AE (60% v 53%, P=0.68) and ACEi-cough (58% vs 53%, P=0.99) patients against 
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Figure 3.8 A Comparison of C-2399A SNP between ACEi-AE; ACEi-cough patients and 
controls. B Analysis of dominant A allele in ACEi-AE and ACEi-cough patients versus 
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Table 7 presents the relationship between the C-2399A SNP and ACEi-AE severity. To my 
knowledge, there is no data in the literature regarding these. The results exhibited no 
significant association between the -2399A allele and ACEi-AE severity as both -2399AC and 
-2399C were significantly higher (P=0.001).  Amongst ACEi-AE cases the -2399A allele was 
significantly higher in males compared to females (9.1% vs2.4%, P=0.01) (Table 7).It should 
noted that the sample size was small for males. 
Table 7 Association of C-2399A SNP and ACEi-AE Grades 
Characteristic A AC C Total P Value 
ACEi-AE 
Grade 
n(%) n(%) n(%) n(%)  
Mild: 1(3.3) 10(33.3) 19(63.4) 40(100.0)  
Moderate: 1(14.3) 2(31.3) 4(57.1) 7(100.0)  
Severe: -------- 8(53.3) 7(46.7) 15(100.0)  
Total 2(100.0) 20(100.0) 30(100.0) 52(100.0) 0.001 
Sex      
Male: 1(9.1) -------- 10(90.9) 11(100.0)  
Female: 1(2.4) 20(48.8) 20(48.8)) 41(100.0)  
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3.2.3 BKR-2 +9/-9 Insertion/Deletion Polymorphism  
 The BKR-2 +9/-9 polymorphism was screened from the DNA of 165 unrelated South 
African hypertensive patients and its association with ACEi-AE or ACEi-cough was 
determined. Genotyping results for the BKR-2 -9/+9 polymorphism results are presented in 
Table 8. Genotypes were in the HWE (P=3.20) among controls. The +9/-9 genotype 
frequencies were similar between males and females (P=0.52) of all cohorts. There was no 
significant association between +9/-9 and blacks, coloureds and whites (P=0.35) of all 
cohorts.  
Table 8: BKR-2 +9/-9 Polymorphism Genotyping Results 























































The -9/-9 genotype was not significantly associated with ACE-AE in case-control study of 
patients (15.4% vs 10.4%, P= 0.45) (figure 3.9A). The -9/-9 genotype was also not 
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with -9/+9 genotype with ACEi-AE (46.2% vs 27.3%, P=0.02) and not with ACEi-cough 
(38.9% vs 27.3%, P=0.21) against in case-control status (figure 3.9A). The +9/+9 genotype 
was significantly lower in ACEi-AE patients controls to compared (38.5% vs 62.3%, 
P=0.007). The +9/+9 was similar between ACEi-cough patients and controls (50% vs 62.3%, 
P=0.21). When -9 allele was treated as dominant (-9/-9 + -9/+9) in ACEi-AE patients against 
controls, the -9 allele was significantly associated with ACEi induced AE (61.5% vs 37.7%, 
P=0.007). Similarly the -9 was treated as dominant in ACEi-cough patients versus controls 
and the results displayed no significant association (50% vs 37.7%, P=0.21).  
 
Figure 3.9 A Comparison of the -9/+9 BKR-2 polymorphism in controls against ACEi-AE 
and ACEi-cough patients. B Analysis of the dominant -9 variant in controls against ACE-AE 
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The relationship between +9/-9 genotype and ACEi-AE severity was sought (Table 9). This 
was done because the -9 variant has been associated with increased severity in HAE patients 
[152]. This has never been investigated in ACEi-AE cases. The results displayed no 
significant association with +9/-9 genotype and ACEi-AE severity (P=0.36). There was also 
no significant association with the +9/-9 genotype with male and female ACEi-AE cases 
(P=0.45). 
Table 9: BKR-2 -9/+9 Polymorphism ACEi-AE Grading Analysis 
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3.2.4 BKR-2 C-58T SNP Screen 
The C-58T SNP in the BKR-2 gene was screened in 165 unrelated South African 
hypertensive individuals and associated with ACEi-AE or ACEi-cough. Table 10 shows 
genotyping results of the BKR-2 C-58T. Genotypes were in HWE (P=6.20) amongst 
controls. The C-58T SNP genotype frequencies displayed a significantly higher CC 
homozygotes and CT heterozygotes in both males and females (P=0.0001) compared to TT 
homozygote. The CC homozygote and CT heterozygote was also a significantly higher in 
blacks, coloureds and whites (P=0.0001) compared to the TT homozygote.   
Table 10: BKR-2 C-58T SNP 
























































The TT homozygote was similar in ACEi-AE patients compared to controls (9.62 % vs 
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controls (13.89% vs 14.28%, P=0.96) (figure 3.10A).  The CT heterozygote was 
significantly associated with ACEi-AE (46.15% vs 24.68%, P=0.01). There was no 
significant association between CT heterozygote and ACEi-cough (33.3% vs 24.68%, 
P=0.33). The CC genotype was similar in both ACEi-AE (44.23% vs 61.03, P=0.06) and 
ACEi-cough (52.78% vs 61.03%, P=0.41) against controls. When the T allele was treated as a 
dominant (i.e TT + CT), no significant association with the -58T allele was observed in both 
ACEi-AE (55.77 vs 38.96, P=0.06) and ACEi-cough (52.78 vs 38.96%, P=0.41) versus 
controls (figure 3.10B). 
 
 
Figure 3.10 A Evaluation of C-58T SNP in ACEi-AE and ACEi-cough patients against 
controls. B Analysis of dominant the of the T allele in ACEi-AE and ACEi-cough patients   
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The C-58T SNP was further associated with ACEi-AE severity and sex within ACEi-AE 
cases (Table 11). The results displayed a significant association C-58T genotype with ACEi-
AE severity (P=0.0001). This was attributed to higher -58C allele in moderate and severe 
ACEi-AE. The -58T allele was significantly higher in female than in male AE cases (12.2% vs 
0%, P=0.0001). This can however be attributed to low sample size in male ACEi-AE 
patients. 
Table 11: BKR-2 C-58T SNP ACEi-AE Grades Analysis 
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Clinically it is imperative to elucidate the pathogenic mechanisms of both ACEi-AE and 
ACEi-cough. Therefore, there is an urgent need to identify predictive markers for the 
development of these side effects. Interestingly, a higher risk for the development of ACEi-
AE has been shown for black Americans suggesting that genetic predisposition might 
modulate the development of ACEi-AE[106;125].  This study examined the association of the 
ACE I/D and BKR-2 +9/-9 polymorphisms and the XPNPEP2 C-2399A and the BKR-2 C-
58T SNPs with ACEi-AE and ACEi-cough in black and coloured South Africans. 
The ACE I/D polymorphism has been associated with cardiovascular and renal diseases such 
as myocardial infarction and idiopathic nephrotic syndrome.  According to the results in this 
study, there appears to be no significant association between the ACE I/D polymorphism and 
ACEi associated AE or cough. The ACE-II genotype has been demonstrated to be dominant in 
black ACEi- and -ARB induced AE patients [155]. Results in this study revealed no 
significant association between the ACE-II genotype ACEi-AE or ACEi-cough. Similarly, the 
ACE-II genotype showed no significant association with ACEi-AE severity. Also there was 
sex-related genotype association in all ACEi-AE cases. 
The C-2399A SNP in the XPNPEP2 gene that encodes aminopeptidase P was previously 
shown to be associated with ACEi-AE as well hypersensitivity reactions in case-controlled 
studies of white patients [12;156]. Moreover, the C-2399A SNP has been associated with 
ACEi-AE in black American males and not whites [157]. In this study, there was no 
significant association of the C-2399A SNP with sex or ethnicity in all cohorts. Furthermore, 
when cases were compared to controls no association was demonstrated between ACEi-AE 
and ACEi-induced cough cases and the C-2399A SNP genotype even when treating -2399A as 
a dominant allele (figure 3.8B).  Moreover, the C-2399A genotype was not associated with 
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The BKR-2 +9/-9 polymorphism has been associated with significantly higher risk of 
coronary risk attributed to hypertension [158]. Whilst the -9/-9 genotype has been associated 
with severe hereditary AE- type I [152]. The +9 allele is associated with decreased BKR-2 
gene transcription and mRNA expression compared to the -9 allele [152]. In the present 
study there was no association with +9/-9 genotype with sex and ethnicity. There was also 
no association with ACEi-AE severity. There was no significant association between the +9/-
9 genotype and ACEi-AE and ACEi-cough cases when treating +9/-9 as an intermediate allele. 
However when treating -9 allele as dominant, there was a significant association of the -9 
allele with ACEi-AE but not ACEi-cough (figure 3.9B). 
The BKR-2 C-58T SNP has been associated with ACEi-cough in Chinese patients [153]. 
Furthermore, the -58C allele has been associated with essential hypertension in black 
Americans [154].  Similar to the BKR-2 -9/-9 genotype, the -58T allele is also associated with 
increased transcription rate of the BKR-2 gene when compared to the -58C allele. In the 
current study the protective -58C allele was significantly higher in males and female but there 
was no association with the defective -58T variant.   The -58C allele was also significantly 
higher in black, coloured and white South Africans. The defective -58T allele was neither 
associated with ACEi-AE nor ACEi-cough in our local population (figure 3.10B). 
Furthermore the protective -58C allele was significantly higher within the ACEi-AE severity 
thus exhibiting no association between -58T and ACEi-AE severity. Moreover, there was sex-
related genotype association with the -58T allele in females with ACEi-AE compared to 
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 Angiotensin converting enzyme (ACE) and aminopeptidase P (APP) are enzymes that are 
responsible for the breakdown of bradykinin (BK).  BK is a proinflammatory, vasodilatory 
nona-peptide that is increased in circulation in events of both ACE inhibitor induced AE and 
cough. During ACE inhibition APP is the main metabolizing enzyme of BK. Therefore 
defects in BK metabolism predispose patients who are taking ACEi to AE and cough.  Serum 
ACE activity has been previously diagnostically measured in diseases such as sarcoidosis and 
myocardial infarction using tripeptide substrates hippuryl-histidine-leucine and z-
phenylalanine-histidine-leucine in a spectroflourometric method. APP activity has been 
previously measured using a flourigenic substrate K(Dnp)PPGK(Abz). 
AIM: To evaluate the role of APP and ACE activities in serum of patients and their 
association with ACEi-induced AE and cough. Furthermore the enzyme activities and 
genotypes were correlated. 
 The objectives of the present work were therefore to: 
1. To determine serum ACE activi y in patients with ACEi-induced AE and cough 
2. To determine the correlation between serum ACE activity and ACE I/D genotype in 
ACEi-induced AE and cough  patients 
3. To analyse the serum levels of APP in patients with ACEi-induced AE and cough. 
4. To assess the correlation between serum APP activity and C2399A SNP genotype in 
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4.2.1. Histidine-Leucine Standard Curve 
A 5mM (10x) histidine-leucine (HL) stock was generated by dissolving 13.41 mg HL (Sigma 
Aldrich, USA) powder in 10ml distilled water.  A 0.5mM HL was made in 1x potassium 
phosphate (1xK2HPO4) buffer of 0.1M K2HPO4; 0.1M KH2PO4, pH 8.3 with 0.3 M NaCl. 
HL standards as set out in Table 10 (Appendix IV) were made from 0.5mM HL in 
1xK2HPO4 buffer. A standard curve was generated by taking 120!l of each standard in 
duplicates in eppendorf tubes, adding 725!l 0.28M NaOH and adding 50!l opthaldialdehyde 
(20mg/ml in 100% methanol) to derivatise for 10min to form a fluorescent adduct. The 
reaction was terminated by adding 100!l 3N HCl and 250!l was transferred to 96 well plate 
and fluorescent intensities were read spectroflourimetrically. A plot of fluorescent intensity 
against nanomoles of HL generated using GraphPad Prism 5 software (Appendix IV).        
 
4.2.2 Hippuryl-Histidine-Leucine Substrate Preparation 
A 5.7mM Hippuryl-histidine-leucine (HHL) was prepared by dissolving 57.4mg HHL 
powder (Sigma Aldrich, USA) in 4.165 ml 0.025 M NaOH and heating at 37oC to ensure that 
HHL was completely dissolved. The mixture was allowed to equilibrate to room temperature 
before adding 4.0ml 5x Potassium Phosphate buffer stock solution (0 .5M K2HPO4; 0.5M 
KH2PO4, pH 8.3) and 2.0ml of 3M NaCl. Lastly 9.835 ml distilled water was added to make 
a 20ml working solution which was stored at -4oC prior the assay. 
 
4.2.3 Z-Phenylalanine-Histidine-Leucine Substrate Preparation 
A 20mM stock solution of z-phenylalanine-histidine-leucine (ZFHL) was made up by 
dissolving 110 mg of ZFHL powder (Bachem, Switzerland)  in 1ml 0.28 M NaOH and 9ml 
distilled water was added to make a final volume of 10ml and aliquots of 2ml were stored at -
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solution (0.5M K2HPO4; 0.5M KH2PO4, pH 8.3; 1.5 M NaCl) and 14 ml distilled water to 
which 2ml ZFHL (20mM) stock solution was added to make 20ml.   
4.2.4 Serum ACE Assay 
Serum ACE activity was determined using a spectroflourimetric assay described by Danilov 
[159] adapted from the method originally developed by Friedland and Silverstein in 1976 
[160].The assay employs tripeptide substrates HHL and ZFHL. The assay is based on the 
principle that ACE cleaves penultimate peptide bond to yield HL moiety that forms a 
fluorescent adduct upon addition of o-pthaldialdehyde. The amount of adduct produced is 
directly proportional to the amount of dipeptide cleaved by ACE and compared to 
fluorescent values obtained from HL standard samples of known product concentration. The 
ACE activity was calculated in mU/ml from the equation: 
 
Patients and control serum was diluted 1:5 in 1x phosphate buffered saline (PBS) and 10!l of 
the diluted serum  was added to 1.5ml eppendorf tube containing 120!l 5.7 mM HHL (Sigma 
Aldrich Chemicals, USA) as well as 120!l 2 mM ZFHL substrate in duplicates on ice, mixed  
by vortexing and incubated at 37oC for 30 minutes . A Blank Zero Time (BZT) sample was 
used as control and prepared according to the protocol apart from containing no serum aliquot 
before. The reaction was then terminated by adding 725!l 0.28 M NaOH and mixed. An equal 
amount of serum/plasma was added to BZT tubes, mixed by vortexing and used as controls 
when calculating the amount of non-enzymatic degradation of both HHL and ZFHL  in 
NaOH {Friedland, 1976 360 /id}. Samples were allowed to reach room temperature before the 
addition of 50!l volume of the fluorimetric agent o-pthaldialdehyde (20mg/ml 100% 
methanol). Samples were thoroughly mixed by vortexing and the reaction was allowed to 
proceed for ten minutes at room temperature. The reaction was terminated by adding 100!l 
3N HCl and mixed. The samples were centrifuged for two-five minutes in a microcentrifuge at 
12000rpm at room temperature to precipitate an unidentified protein-o-pthaldialdehyde 
complex that might interfere with fluorescent analysis. 
ACE Activity = 
I 
nmol ofHL obtained from the , ample X total reaction ""[,,me 
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A 250!l aliquot of the supernatant was transferred to 96-well microtitre plate for adduct 
analysis. Samples fluorescent intensities were determined on the Cary ECLIPSE flourimeter 
(Varian, Walnut Creek, CA) at the excitation and emission wavelength of 360 and 486nm 
respectively. The ZFHL/HHL ratio was then calculated to determine presence of inhibitor in 
blood. A ratio > 1.10 indicates the presence of ACEi and that the patient is not compliant. 
4.2.5 Serum Dilution and Determination of ACE Stability  
It has been previously shown that ACE is inhibited by unidentified low molecular weight 
endogenous inhibitors in serum, urine and other tissues [159].It was therefore decided to 
dilute serum in 1x PBS in a dilution series as follows; 1:2, 1:4 and 1:8 simultaneously with 
undiluted serum so that the effect of these endogenous inhibitors can be observed and 
minimized with subsequent assays. ACE activity was then determined as described before in 
section 4.2.4.    
Serum ACE stability was determined by using serum stored at -80oC diluted 1:5 in PBS, 
aliquoted and stored at room temperature (20–22oC) and +4oC for a two week period. At the 
indicated times, 20!l of ACE solutions were added to 120!l of substrate (5.7 mM HHL or 2 
mM ZPHL), and ACE activity was determined as described in section 4.2.4. 
 
4.2.6 ACE Inhibition 
 Clinically used ACEi lisinopril (10mg) was dissolved in distilled water to make a 1mM stock. 
Different concentrations of lisinopril (0, 0.1, 0.3, 1, 3, 10, 30 nM) were then made-up in 1x 
potassium phosphate buffer. Serum was diluted 1:5 in 1XPBS and 180!l was added to the 
eppendorf tube containing 20!l of each inhibitor concentration in triplicates. The mixture was 
mixed by vortexing and pre-incubated for 2 hours at room temperature so that the enzyme 
and inhibitor reaches the equilibrium. The residual ACE activity was determined with 5mM 
HHL and 2 mM ZFHL, as described earlier in section 4.2.4. The ZFHL/HHL ratio was then 
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4.2.7 Serum APP Assay 
Serum APP activity was assessed using the quenched fluorescent substrate K(Dnp)Pro-Pro-
Gly-Leu(Abz) (PPGK), using a method developed by Molinaro in 2005 [161].The Abz ("-
aminobenzoic acid) acts fluorescent donor group of the substrate whereas Dnp (2,4 
dinitrophenyl) is the fluorescent acceptor group. The substrate mimics the NH2 terminus of 
BK/ or des-AR9BK and is highly specific for APP activity. APP cleaves the substrate 
between the Pro-Pro bond and thus results in increase in fluorescence over time.  One unit of 
APP corresponds to 1 pmol of PPGK hydrolyzed. 
The flourogenic substrate PPGK (a kind gift from A.K Carmona) was dissolved in 1ml 100% 
DMSO buffer to make 10 mM stock solution. Using the extinction coefficient of 
E365m=17300 m
-1cm-1. The concentration of 1/100 dilution in distilled water was determined 
and 1mM aliquots were made and stored at -20oC.  
Serum was diluted 1:10 in 1mM HEPES buffer pH 7.5 at room temperature. The PPGK 
substrate was diluted 1:125 from 1mM stock in 1mM HEPES buffer pH 7.5 at room 
temperature. 50!l patient sample was added to 250!l substrate in duplicates in eppendorf 
tubes and mixed by vortexing. An aliquot of 300!l was transferred to 96 well microtitre plate. 
Fluorescent intensities were then were read on a Cary ECLIPSE flourimeter (Varian, Walnut 
Creek, CA) at the excitation and emission wavelength of 320 and 420nm in that order at 0min, 
15min, 30min and 60min.  A standard curve was generated using a series of standard samples 
to convert fluorescence to pmol of the product from total hydrolysis of the substrate 
(AppendixIV). Standard samples were primed in the same manner as the patient samples.  
The enzymatic activity was calculated as picomoles per minute per milliliter plasma 
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4.2.8 Serum APP Stability  
For serum APP activity, fresh serum was diluted in 1mM Hepes buffer pH 7.5 to give a APP 
activity of pmol/min/ml and stored at -80oC, +4oC and room temperature for two weeks. At 
specific times 50!l of sample was added to 250!l PPGK substrate and APP activity was 
determined using the above-mentioned method.  
 
4.2.9 Statistical Analysis 
Enzymatic results were evaluated using STATISTICA version 9 software (Stasoft®, USA). 
Data was first evaluated for normal distribution using the Shapiro-Wilk’s test (p>0.05 for 
normal distribution). Paired t-Test for dependent samples was used to analyze control 
patients when on and off treatment for normally distributed data (data reported as Mean±SD) 
whereas Wilcoxon’s nonparametric t-Test was used analyze data that is not normally 
distributed (data presented as Median, 25-75% quartile with minimum and maximum value). 
One way ANOVA (Tukey’s multiple comparison test) was used to compare between means 
of controls, cough and angioedema subjects for normally distributed data. Kruskal-Wallis 
nonparametric ANOVA test was used to compare differences treated controls, cough and 
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4.3.1 Validation of the Serum ACE Activity Assay 
Serum ACE levels were determined simultaneously in undiluted sera and compared to a 
dilution series to determine the effect of the endogenous inhibitor on ACE activity. Figure 
4.1 shows a pooled serum sample from three normotensive controls. This was done because a 
low molecular weight endogenous ACE inhibitor was shown to interfere with ACE activity 
level measurements in serum [159]. The results showed that with increasing dilution (1:2 
through to 1:8) that there was a progressive increase in ACE activity with both HHL and 
ZFHL substrates compared to undiluted (figure 4.1A). The ACE activity was higher when 
using the ZFHL compared to HHL substrate from undiluted serum through to 1:8 dilution. 
There was a decrease in ZFHL/HHL ratio with increasing serum dilutions (figure 4.1B). The 
undiluted serum and the 1:2dilution showed a highest ZFHL/HHL ratio of 1.54 and 1.44 
(normal <1.10) respectively indicating the presence of inhibitor.  The 1:4 and 1:8 dilutions 
showed a lower ZFHL/HHL ratio of 1.10 and 1.09 respectively which meant that the effect 
of the endogenous inhibitor was minimized. It was then decided that a 1:5 dilution would be 
used for subsequent assays as further dilution would compromise fluorescent intensities.  
Figure 4.1: A ACE activity of serum serial dilutions of pooled serum using HHL and ZFHL 
substrates. Activity is multiplied by dilution factor for each dilution. A dilutional increase of 
ACE activity is shown indicating true inhibitory effect. B ZFHL/HHL ratio confirming the 
presence of inhibitor in undiluted sera and 1:2 dilution compared to 1:4 and 1:8 dilutions. 
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Due to prolonged storage of serum samples, ACE stability was assessed after storing the 
serum at different temperatures for two weeks.  Figure 4.2 describes ACE activity using 
samples from the same individual to achieve this objective. It was determined that ACE was 
very stable with no significant loss of activity over two weeks at +4oC (20.1 mU/ml) and 
room temperature (20.3mU/ml) when compared sample stored -80oC (20mU/ml). 
 
Figure 4.2: The effect of temperature on the stability of ACE. The assay was repeated three 
times and the intra-assay and inter-assay variability was less than 10%. 
4.3.2 ACE Inhibition 
To investigate the detection limit for the presence of ACEi in human blood, the ZFHL/HHL 
ratio was determined after incubating serum enzyme solution with varying concentrations of 
lisinopril. A significant increase of the ZFHL/HHL ratio was observed at 0.3nM lisinopril 
consistent with reports in the literature (figure 4.3) [159]. Bearing in mind that clinically 
ACEi are given to patients at a dose of 10mg per day, per kg, 2 times daily, it has been shown 
that at peak the concentration of ACEi is 50nM and 5nM after 24 hours in human blood 
(154). Thus this analysis is sensitive enough to detect the concentration of ACEi in human 
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Figure 4.3: Effect of ACEi lisinopril on ZFHL and HHL substrate hydrolysis. The assay 
was repeated three times intra and inter- assay variation was less 10%. 
4.3.3 Analysis of Serum ACE Activity in Patients with ACEi-associated AE and Cough 
ACE activity was assayed in controls, ACEi-AE and ACEi-cough patients simultaneously 
using 5.7 mM HHL and 2 mM ZFHL substrates (figure 4.4A). Serum samples from a group 
of 117 patients comprising of 29 controls, 52 AE and 36 ACEi-induced cough patients were 
assayed for ACE activity.  For controls ACE activity was determined they were taking 
enalapril and when they were not taking enalapril. Figure 4.4B shows the Shapiro-Wilk’s 
test for normality of ACEi-AE and ACEi-cough patients including controls off enalapril. The 
data showed a Gaussian distribution (symmetrical) which meant that there was a normal 
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Mean ACE Activity = 29.2724-0.0588*x; 0.95 Conf.Int. A
Figure 4.4: A Scatter plot of ACE activity of 117 patients off enalapril in the study. B 
Histogram of the Shapiro-Wilk’s test showing normal distribution of 117 patient’s ACE 
activity off enalapril.  
There was a significant difference in the mean ACE activity of controls when they taking 
enalapril (9mU/ml) compared to when they stopped taking enalapril (34mU/ml) (figure 
4.5A).  To determine the compliance of the control cohort, the ZFHL/HHL ratio was 
determined for serum samples taken while on and off enalapril. The ZFHL/HHL ratio was 
significantly higher when controls were on enalapril compared to when they were off enalapril 
(3.25 vs 0.91, P=0.0001). This unequ vocally proved that the controls were off treatment for 
the specified time period of 48 hours.  
 
Figure 4.5: A A paired T-test was used to compare the mean ACE activity of patients on 
and off enalapril. B ZFHL/HHL ratio to check for control compliance. 
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The mean ACE activities of controls, cough and angioedema patients were compared using 
Tukey’s multiple comparison test. There was a significant difference in the mean ACE 
activity of treated patients against both cough (P=0.000114) and AE (P=0.000114) patients 
(fig4.6). There was also a significant difference in the mean ACE activity of cough patient 
versus AE (P=0.000298) patients. It should be noted that all patients were off enalapril.  
 
Figure 4.6: Box and Whisker plot of one way analysis of variance of serum ACE levels in 
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4.3.6 Correlation between Serum ACE Activity and ACE Genotype in Patients 
The ACE activity in serum was correlated with the ACE genotype previously determined in 
chapter 3 from all cohorts including controls using the Tukey’s multiple comparison post hoc 
ANOVA test (figure 4.7). The mean activities of serum ACE was surprisingly similar for the 
ACE-II (ACE activity=23.94mU/ml), ACE-ID (ACE activity=24.49mU/ml) and ACE-DD 
(ACE activity=23.09mU/ml) in contrast to reports in the literature that ACE-II genotype 











Figure 4.7:  A box–and-whisker plot of one way analysis of variance of correlation between 
ACE phenotype and the ACE insertion/deletion genotype in all patients. 
 
The activity of ACE in serum was then correlated with ACE genotype in controls, ACEi-AE 
and ACEi-cough patients (figure 4.8).  It was found that ACE II homozygotes in controls 
had significantly higher mean ACE activity compared to both ACEi-AE (35.68mU/ml vs 
17.05mU/ml, P=0.001) and cough (35.68mU/ml vs 23.05mU/ml, P=0.01) patients. There was 
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patients (23.05mU/ml vs 17.05mU/ml, P=0.05).With regards to ACE ID heterozygote 
genotype, the ACE activity was significantly higher in controls compared to ACEi-AE 
(34.50mU/ml vs 17.61mU/ml, P= 0.001) and ACEi-cough (34.50mU/ml) vs 25.36mU/ml, P= 
0.01) patients. No significant difference was observed between ACEi-AE and ACEi-cough 
patients (17.61mU/ml vs 25.36mU/ml, P= 0.05) ACE activity. Lastly ACE DD genotype 
showed significantly higher ACE activity in controls than in ACEi-AE (33.40mU/ml vs 
18.74mU/ml, P=0.001) and ACEi-cough (33.40mU/ml vs 21.62mU/ml, P=0.01) patients. No 
significant difference was shown between ACEi-AE and ACEi-cough patients (18.74mU/ml 
vs 21.62mU/ml, P= 0.05). Overall there was no significant difference in ACE activity and 
ACE genotype correlation in all cohorts. 
 
Figure 4.8: Bar chart of Correlation between serum ACE activity and ACE genotype in 
controls against ACEi-AE and ACEi-cough patients. Blue bars signify controls; red bars 
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4.3.5 The determination of Serum APP Activity 
APP activity was checked for stability in serum by incubating serum samples at -80oC, room 
temperature and +4oC for two weeks. Figure 4.9 shows that there was no significant 
reduction in APP activity at various temperatures. The APP activity was 410.9pmol/ml, 
471.8pmol/min/ml and 474.4pmol/min/ml at +4oC, room temperature and -80oC respectively. 
 
Figure 4.9: Determination of APP activity of serum samples stored at different conditions 
for period of two weeks. RT, room temperature. 
APP activity was determined in serum samples from 117 patients comprising 29 treated 
controls, 36 ACEi cough patients and 52 angioedema patients. Figure 4.10A demonstrates an 
example of serum APP activity of angioedema patients. For treated controls, APP activity 
was measured when patients were on enalapril and off enalapril for 36 hours similar to what 
was done with the ACE activity determination.  With regards to the APP activity, the data 
was not normally distributed with the Shapiro-Wilk’s test because the data was skewed to 
the right instead of being symmetrical (p=0.0001) (figure 4.10B). Consequently, 
nonparametric tests were used for further statistical analysis.  
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Figure 4.10: A Scatter plot of 117 patient’s APP activity off enalapril. B Histogram of the 
Shapiro-Wilk’s test for normal distribution of serum APP eznyme activity in all patients off 
enalapril treatment. 
 For controls, the APP activity was significantly higher when patients were off enalapril 
compared to when they were on enalapril (125.54pmol/min/ml vs (55.32pol/min/ml, 









Figure4.11: Wilcoxon Non-parametric t-Test for dependent variables of treated control 
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The APP activity was significantly lower in both ACEi-AE (320.46 pmol/min/ml vs 110.12 
pmol/min/ml P=0.0007) and ACEi-cough (320.46 pmol/min/ml vs 100.25 pmol/min/ml 
P=0.0003) patients when compared to treated controls (figure 4.12). There was no 
significant difference in the APP activity of ACEi-AE against ACEi-cough (110.12 








Figure 4.12:  Box and Whisker plot of the comparison of APP activity between controls 
against ACEi-AE and ACEi-cough patients using Kruskal-Wallis nonparametric ANOVA 
test.  
4.3.6 Correlation between APP Activity and APP Genotype in Patients 
When APP activity was correlated with the APP genotype in all patients, there was no 
significant difference between activity 2399A and 2399C (266.05pmol/mon/ml vs 
155.65pmol/min/ml, P=1.00) disputing reports in the literature that people with the A allele 
had a significantly lower APP activity (figure 4.13). There was no significant difference 
when 2399A was compared to 2399AC (266.05pmol/min/ml vs 100.23pmol/min/ml, 
P=0.232). The 2399C allele showed a significantly higher APP activity when compared to 
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Figure 4.13:  Box and Whisker plot of Correlation between APP activity and C2399A SNP 
of al cohorts using the Kruskal Wallis ANOVA Nonparametric test for three or more 
independent variables.  
APP activity was correlated with APP genotype in controls, ACEi-AE and ACEi-cough 
patients. Figure 4.14 presents comparison between C2339A SNP genotypes and APP 
activity of controls against ACEi-AE and ACEi-cough patients. The APP activity with 
regards to 2399A genotype was significantly higher in controls compared to ACEi-AE 
patients (344.16pmol/min/ml vs 57.25pmol/min/ml, P=0.0.1). The APP activity 2399A 
genotype was also significantly higher in cough against ACEi-AE patients 
(389.25pmol/min/ml vs 57.25pmol/min/ml, P=0.01). No significant difference in 2399A 
genotype APP activity was observed between controls and ACEi-cough patients (344.16 
pmol/min/ml vs 389.25 pmol/min/ml, P=0.05). The 2399AC genotype showed significantly 
higher APP activity in controls compared to ACEi-AE (265.17pmol/min/ml vs 
145.97pmol/min/ml, P=0.01) and ACEi-cough patients (265.17pmol/min/ml vs 
109.63pmol/min/ml, P=0.01). No significant difference was observed between ACEi-AE and 
cough (145.97pmol/min/ml vs 109.63pmol/min/ml, P=0.05) 2399AC APP activity.  The 
2399C genotype APP activity was significantly higher in controls than in ACEi-AE 
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(258.89pmol/min/ml vs 144.57pmol/min/ml, P=0.01) and ACEi-cough (258.89pmol/min/ml vs 
127.13 pmol/min/ml, P=0.01) patients. There was no significant difference in 2399C 
genotype APP activity between ACEi-AE and ACEi-cough patients (144.57pmol/min/ml v 
127.13pmol/min/ml, P=0.05).  Suprisingly the 2399A genotype APP activity was higher than 
2399AC and 2399C genotypes in controls.  The 2399A genotype APP activity was also 
significantly higher in cough patients than both 2399AC and 2399C. The 2399A genotype 
APP activity was significantly lower than both the 2399 AC and 2399 C in ACEi-AE 
patients. 
 
Figure 4.14: Bar Chart presenting correlation between APP activity and APP genotype in 
controls against ACEi-AE and ACEi-cough patients. Blue bars represent controls; red bars 
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About 40 000-280 000 patients that take ACE inhibitors are affected by a rare but potentially 
life threatening AE[157;162].  Blacks,  coloureds , females, and people that smoke and suffer 
from seasonal allergies are at the greater risk of experiencing this adverse effect suggesting that 
genetic and environmental factors influence the development of ACEi-AE [103;125;127]. 
Earlier investigations postulate that defective degradation of the vasoactive peptide BK leads 
to ACEi-AE and ACEi-cough [134]. BK is primarily degraded by ACE and APP and during 
ACE inhibition APP assumes the primary role [12]. The relationship of correlation between 
ACE activity and ACE I/ polymorphism as well as the relationship between APP activity 
and the previously described functional polymorphism in the XPNPEP2 gene were assessed 
in ACEi-AE and ACEi-cough South African coloured and black patients.   
 A serum ACE activity assay was validated by checking the effect of endogenous inhibitors 
on ACE activity and by assessing the effect temperature has on ACE stability.  The 
measurement of serum ACE activity  has been shown to be affected by the presence of 
endogenous low molecular weight inhibitors [159].  A serial dilution was therefore performed 
to reduce this effect and it revealed that with increasing dilution ACE activity increases 
compared to undiluted sera when using both HHL and ZFHL as substrates (figure 4.1A). 
The increased ZFHL/HHL ratio in undiluted and a 1:2 dilution of serum, when compared to 
1:4 and 1:8 dilutions, further confirmed the presence of inhibitor(s) (figure 4.1B). The 
activity of ACE was shown be stable at temperatures of -80 °C, 4 °C and 22 °C after two 
weeks (figure 4.2).  
ACE inhibitors are routinely used as first line treatment for hypertension, congestive heart 
failure and diabetic nephropathy. However determination of these drugs in human blood 
remains tedious due to difficulty in extracting ACE inhibiting compounds, the technology that 
is required for their analysis, and their low concentration in serum [163-166]. Recently the 
use of the ratio of ACE activities using the substrates ZFHL and HHL has been employed to 
detect the presence of ACEi in human blood [159]. The fact that binding of ACEi 
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inexpensive method is an effective way of detecting ACEi in sera. The sensitivity of the assay 
was as low as 0.3nM with the widely used ACEi lisinopril. Therefore this assay can be used 
to quantify the presence of ACEi in blood and the extent of inhibition.   A big advantage of 
this approach is that the quantification of the degree of ACE inhibition via the ZFHL/HHL 
ratio does not need knowledge of the initial ACE activity of a given patient [159]. 
Serum ACE activity was investigated in controls when they were on and off ACEi enalapril. 
It was shown that ACE activity was significantly higher when patients were not taking 
enalapril compared to when they were taking enalapril indicating in vivo ACE inhibition 
(figure 4.5A). The lower ZFHL/HHL ratios further confirmed that these patients were 
compliant (figure 4.5B) thus emphasizing the clinical value of using the ZFHL/HHL ratio in 
determining ACE inhibition. Furthermore, ACE activity was assessed in ACEi-AE and ACEi-
cough patients and found to be significantly lower activity in both cases than controls. Since 
ACEi-AE and ACEi-cough patients were no longer taking enalapril the reason for their lower 
ACE activity might be due to decreased induction of ACE synthesis in endothelial cells 
mediated by unknown transcriptional element/s. It has previously been shown that chronic 
ACE inhibition leads to increased serum ACE levels[167]. Importantly, the diuretic, 
hydrochlorothiazide has been shown to have ACE inhibitory capability[168] and thus might 
have an effect on ACE levels in ACEi-AE and ACEi-cough patients in this study. ACE 
activity was also considerably higher in ACEi-cough patients than ACEi-AE patients. The 
reason for this is unclear however it is possible that ACEi-cough patients have higher ACE 
expression than ACEi-AE patients leading to higher enzyme activity. Clearly, this requires 
further investigation.  
Previous work has shown that levels of plasma and cellular ACE are strongly influenced by 
genetic factors [169-172]. Earlier investigations have showed that individuals with the ACE-II 
genotype have lower ACE activity than the ACE-DD genotype, with the ACE-ID individuals 
having intermediate ACE levels [171;172]. Correlation between ACE activity and  the ACE 
I/D genotype has been investigated in other disease states [173;174].   In the present study 
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was no significant difference in ACE activity between II, ID and DD genotypes (figure 4.7). 
This might, in part, be due to large inter-individual variability in ACE activity. Indeed other 
studies have proven that the ACE I/D is marker for ACE activity and accounts for 28-40% 
inter-individual variability in serum ACE activity or immunoreactive levels [170;171]. 
Moreover, the relationship between the activity of ACE in serum and the ACE genotypes 
was sought in both ACEi-AE and ACEi-cough patients. The correlation between the ACE-II 
homozygotes displayed significantly higher ACE activity in controls compared to ACEi-AE 
and ACEi-cough patients. Similarly, the ACE-ID genotype exhibited higher activity in 
controls versus ACEi-AE and ACEi-cough patients. The ACE-DD genotype also revealed 
higher ACE activity in controls compared to ACEi-AE and ACEi-cough patients.  
The activity of APP was shown to be stable at varying temperatures. APP activity was 
significantly lower in controls when they were on enalapril compared to when patients were 
not taking enalapril.  The activity of APP purified from pig renal cortex and mouse lung has 
been previously illustrated to be inhibited by enalapril at nanomolar concentrations [175;176].  
The present work unambiguously proves that enalapril inhibits APP activity in human serum.  
Previous work has demonstrated that APP activity is significantly lower in ACEi-AE 
patients in a case-control study [12]. A similar trend was observed in the present study 
whereby APP activity displayed significantly lower activity ACEi-AE patients compared to 
controls. The present study also further showed APP activity in ACEi-cough is significantly 
lower than that of controls. This unequivocally proves that both ACEi-AE and ACEi-AE are 
associated with decreased APP activity.  
APP is a zinc metalloprotease attached to the membrane by a GPI anchor. It is encoded by 
the XPNPEP2 gene and the C-2399A SNP has been shown to be associated with APP altered 
activity [12].  The -2399A genotype is associated with decreased APP activity whereas both 
the -2399AC and the -2399C are associated with increased activity. The relationship between 
the C-2399A SNP was therefore examined in our local population. Overall there was no 
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attributed to low sample size in patients that had -2399A. Furthermore, the XPNPEP2 gene 
accounts for 34% heritability of plasma APP activity [12]. This means other genetic loci 
might be controlling plasma APP activity in our population and needs further investigation. 
Nonetheless, the correlation between serum APP activity and the APP genotype was 
assessed in controls against ACEi-AE and ACEi-cough.  The results revealed that -2399A 
genotype in both controls and ACEi-cough patients had significantly higher APP than ACEi-
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Much research has been done on the clinical and molecular bases of the ACEi side effects. 
However the mechanism(s) that cause ACEi-AE and ACEi-cough are still not fully 
understood.  The widely most accepted mechanism is that inhibition of ACE increases kinin 
levels resulting in the activation of a proinflammatory response and nitric oxide generation 
[137;177]. Nonetheless, relatively little is known about the genetic susceptibility of 
hypertensive patients to ACEi-induced AE and cough. Relatively few studies have been 
carried out to determine whether selected polymorphism in ACE, XPNPEP2 and BKR-2 
predispose patients to ACEi-related side effects. Most of these studies have been carried out 
in Caucasian and Chinese/Korean/Japanese patients [153;178-181] .   
The aim of this thesis was to assess the relationship between ACEi-AE a d ACEi-cough and 
known genetic polymorphisms in the ACE, XPNPEP2 and the BKR-2 genes in black and 
coloured South Africans in the Western Cape. Furthermore, ACE and APP activities were 
measured in serum and correlated with genotypes in ACEi-AE and ACEi-cough patients. 
Much work has been done on the ACE I/D polymorphism and its association with many 
diseases and physiological conditions. The ACE-DD genotype has been associated with 
asthma in one study [182]. However, in another study the ACE-DD genotype was 
demonstrated to have no meaningful effect on asthma[183].   The ACE-II genotype has been 
associated with greater risk of developing ACEi-cough [184]. In this study however, there 
was no significant association between the ACE I/D polymorphism and ACEi-AE or ACEi-
cough.  The ACE gene I/D polymorphism has been shown to affect the levels of serum ACE 
[171]. In this study, ACE activity in both ACEi-AE and ACEi-cough patients was lower than 
that of controls.  When ACE activity was correlated with genotype, it was higher in controls 
compared to ACEi-AE and ACEi-cough patients with all genotypes. These data suggests that 
low ACE activity predisposes patients to ACEi-AE and ACEi-cough. However, the 
association of the ACE I/D polymorphism with ACEi-AE and ACEi-cough remains’ unclear 
and needs further investigation with a larger sample size to make more meaningful 
conclusions.   
In order to elucidate the further the molecular basis of ACEi related side effects the role of the 
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been shown to be associated with serum APP activity and ACEi-AE [12;181]. The functional 
-2399A variant is associated with significantly lower APP activity compared to -2399AC and 
-2399C alleles. This makes patients with the -2399A allele more susceptible to developing 
ACEi associated AE and cough. In contrast, this study showed no clear association between 
the C-2399A genotype and ACEi-AE or ACEi-cough.  
 APP plays a pivotal role in degrading BK and des-Arg9BK during ACE inhibition. Therefore 
decreased APP activity leads to high BK and des-Arg9BK in the bloodstream leading to 
inflammation. Indeed studies showed that ACEi-AE is associated with slower degradation of 
both BK and des-Arg9BK due decreased APP activity [138]. Additionally, earlier studies 
suggest that black Americans exhibit increased sensitivity to the effects of bradykinin-induced 
vascular permeability compared to their white counterparts [185].  In the present study APP 
activity was decreased in both ACEi-AE and ACEi-cough patients compared to controls. 
When APP activity was correlated with the C-2399A genotype, APP activity was lower in 
ACEi-AE patients, but not in ACEi-cough patients. However, it is difficult to conclude 
unambiguously that C-2399A is/not associated with both ACEi-AE and ACEi-cough. 
Furthermore APP activity has been shown to be decreased in men compared to women [157]. 
It can thus be postulated that sex hormones contribute to sex differences in enzyme activity.  
Indeed, it has been reported that progesterone increases APP activity [186]. The effect of 
estrogen on APP expression or activity has not being reported and thus needs further 
investigation. Androgen increases APP activity in patients with HAE-I giving rise to the 
notion that increased testosterone concentrations in men is unlikely to account for sex 
differences [187]. Importantly, it has been reported that XPNPEP2 escapes X-
inactivation[188]. 
Defects in multiple pathways may contribute to the etiology of both ACEi-AE and ACEi-
cough. BK increases vascular permeability and stimulates cough reflex in the lung by 
stimulating the BKR-2 receptor. Interestingly, it has been suggested that the therapeutic 
effect of ACEi may involve activation of the BKR-2 [31;31]. Indeed, it was demonstrated 
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The BKR-2 +9/-9 polymorphism has been shown to be clinically relevant with the -9 variant 
showing increased vasodilation during ACE inhibition. Furthermore the -9 allele is associated 
with symptomatic HAE in cases of CINH deficiency[152]. To my knowledge, this first 
study to associate both ACEi-AE and ACEi-cough with the +9/-9 BKR-2 polymorphism. 
The results showed a significant association with -9 variant with ACEi-AE but not ACEi-
cough.  Even though this data is interesting, further exploration is needed. 
Some reports have analyzed the role of genetic variant C-58T in the BKR-2 in ACEi-AE and 
ACEi-cough and showed no association [180;190]. In contrast, two reports showed an 
association with C-58T with ACEi-cough [153;191]. In this study the analysis revealed no 
association between ACEi-AE and ACEi-cough and C-58T genotype. 
BK stimulates the release of substance P from nerve ends and substances P increases vascular 
permeability through stimulation of the neurokinin type 1 receptor (NKR-1).  In animal 
models blocking NKR-1 prevents ACEi-AE.  Substance P has also been postulated to be 
increased in ACEi-AE and ACEi-cough events [192;193]. Thus variation in enzymes 
responsible for inactivation of both BK and substance P or BK and substance P receptors 
may contribute to both ACEi-AE and ACEi-cough. Interestingly, NKR-1 Gly231Glu 
polymorphism has been associated with ACEi-cough in Korean patients [143;194]. BK is 
degraded by ACE, APP and NEP whilst substance P is broken down by ACE, dipeptidyl 
peptidase IV (DPPIV) and NEP. It has been reported previously that DPPIV is decreased in 
some patients with ACEi-AE[193;195]. However no functional polymorphism has been 
found in the DPPIV gene and associated with ACEi-AE and ACEi-cough. Therefore next 
logical step would be to investigate functional polymorphism/s in the DPPIV gene and their 
association with DPPIV activity and therefore ACEi-AE and ACEi-cough.   
Dual inhibition of ACE and NEP leads to three times higher risk of developing ACEi-AE 
compared with ACEi treatment alone. Interestingly, the rs2016848 variant in the NEP has 
been associated with ACEi-cough in one study [177]. Therefore this needs further exploration 
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BK also causes the secondary activation of prostaglandins especially PGE2 and PGI2 and the 
former acts on EP 1, 2, 3 and 4 receptors to exert its biological effects. EP receptors are 
encoded by PTGER1-PTGER4 genes and a recent report indicates that an rs11209716 
variant in the PTGER3 is associated with ACEi-cough. The relationship between 
prostaglandins and PGI2 with ACEi-AE and ACEi-cough has been less explored. 
Nonetheless, PGE2 has been shown to mediate cough via the EP3 receptor in asthmatic 
patients [196;197]. Moreover, PGE2 analog, beraprost is a novel therapeutic option for cough 
[197].  
In summary this thesis explored the association between known genetic polymorphisms in 
the ACE, XPNPEP2 and BKR-2 genes with the pathogenesis of ACEi-AE and ACEi-cough 
in black and coloured South Africans in the Western Cape. Further studies are needed to 
confirm/disprove the findings of the current study. Furthermore, it is difficult rule out the 
possibility of false-negative/positive results due to limitations in sample size and the number 
of tests performed in this study. The difficulty in elucidating the genetic basis of complex 
diseases is entrenched in a lot of factors that have an effect in the development of a disease. 
Some of the genetic effects may interact in multifaceted ways that are not detected by single 
locus methodology used in the study. Therefore in future, analysis of gene-gene interactions 
in black and coloured South Africans are crucial for a better understanding of the contribution 
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Dear Prof Rayner  
 
 
PROJECT TITLE: ANALYSIS OF A VARIANT IN XPNPEP2 IN BLACK AFRICAN 
AND COLOURED SOUTH AFRICANS PRESENTING WITH ANGIOEDEMA 
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patients in other specialist clinics, we recommend that you approach the physicians / heads 
of the particular clinics where you are most likely to source your participants and explain the 
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Please note that the ongoing ethical conduct of the study remains the responsibility of the 
principaJ investigator.  
 






PROFESSOR M BLOCKMAN  














PATIENT INFORMATION AND INFORMED CONSENT: 
Introduction: We are conducting research into the causes of angioedema, an important complication of ACE 
inhibitors, a commonly used blood pressure pill. We need to take 5 blood samples to help us analyse differences 
and activity of a certain gene that may cause angioedema. We are specifically analysing the XPNPEP2 gene, 
and the activity of certain enzymes (serum ACE and aminopeptidase activity) and inflammatory mediators 
(bradykinin) related to this gene while you are taking the ACE inhibitor and after stopping the medication. Your 
doctor will only stop the ACE inhibitor if it is safe for you to do this. 
1. I,          , hereby consent that my blood 
cells be analysed for genetic changes in the XPNPEP2 gene. 
2. I request that no portion of the sample be stored for later use.        (MARK IF APPLICABLE) 
Or 
I request that a portion of the sample be stored indefinitely for (DELETE WHERE NOT APPLICABLE) 
a) possible re-analysis 
b) analysis for benefits of members of my immediate family 
c) research purposes, subject to the approval of the University of Cape Town Research Ethics Committee, 
provided that any information from such research remain confidential. 
3. The results of the analysis will be made known to me or my doctor if and when available. In addition I 
authorise that they be made known to the following: (DELETE WHERE NOT APPLICABLE) 
a) other doctors involved in my care 
b) the following family members 
c) other 
4. I have been informed that: 
a) There are risks and benefits of genetic analysis of stored material 
b) The analysis procedure is specific to this genetic condition mentioned above, and can not determine the 
complete genetic make up of an individual 
c) The laboratory is under an obligation to maintain confidentiality 
d) Genetic analysis may not be informative for myself or other family members 
e) There may be no direct benefit to me 
f) Even in the best of conditions, current technology is not perfect and there is a possibility of incorrect results 
5. I understand I can withdraw my consent for any aspect of the above at any time without affecting my future 
medical care. 
6. ALL OF THE ABOVE HAS BEEN EXPLAINED TO ME IN A LANGUAGE THAT I CAN 
UNDERSTAND AND MY QUESTIONS HAVE BEEN ANSWERED 
 
















Buffers and solutions 
 Potassium Phosphate Buffer, pH 8.3 containing 3M NaCl. 
A 5X stock was prepared: 0.5M KH2PO4; 0.5 MK2HPO4, pH 8.3 and 3M NaCl 
(Mw=58.5g).  
3.42g KH2PO4 (Mw= 136.99); 4.35g K2HPO4 (Mw=174.18) and 8.766g NaCl 
(Mw=58.5) in 50ml of distilled water. Adjusted pH to 8.3.  
Working solution:1X buffer. 
 
Phosphate Buffered Saline 
A 1X stock was prepared:  0.2M Na2HPO4.2H2O; 0.8M KH2PO4; 0.3M KCl and 
7x10-3M NaCl. 
1.15g Na2HPO4.2H2O (Mw=177.99); 0.23g KH2PO4 (Mw=174.18); 0.23g KCl (Mw= 
74.56); 8g NaCl (Mw=58.5) in 1000ml distilled water  
 
0.28M NaOH 
Weight 11.2g NaOH (Mw=40.00) pellets and made-up to 1000ml with distilled. 
 
0.025M NaOH 




15ml 32% HCl made up to 50ml with distilled water. 
 
 o-pthaldialdehyde (150 mM) 
 20 mg o-pthaldialdehyde (Mw= 134.1)(Sigma) in 1.0 ml  methanol. 
 
10 % AMPS  
















His-Leu standard curve 
His-Leu (HL) standards 
Stock solution of His-Leu (Mw=268.3) (Sigma): 
13.41 mg dissolved in 10 ml sterile distilled water  
HL standards set out in Table 10 were made in 1xK2HPO4 buffer. 
Fluorescence was measured at !Ex=360 and !Em=486 nm on a Cary Eclipse 
fluorometric plate reader (Varian).   
A standard curve of fluorescent units vs nmoles HL was plotted using GraphPad 
Prism 4.01. HL. Slope was determined via linear regression analysis. 
 
Table 10: HL Standards 
             HL Concentration          HL in 1xK2HPO4                  1xK2HPO4(ml)   
               (nmol per 30!l)                buffer (ml)  
1                  0                                      0                                           5.00 
2                 0.30                                   0.1                                       4.90 
3                 0.60                                   0.2                                       4.75 
4                 1.50                                   0.5                                       4.50 
5                 2.25                                   0.75                                     4.25 
6                 3.00                                   1.0                                       4.00     









Synthetic tripeptide substrates: Hip-His-Leu and Z-Phe-His-Leu 
HL Standard Curve



























5.7 mM Hippuryl-His-Leu  
48.5 mg N-Hippuryl-His-Leu tetrahydrate (Mw= 501.5) (Sigma)   dissolved in 4.165 
ml heated 0.025 M NaOH. Then added: 4.0 ml 5 x Potassium Phosphate buffer, pH 
8.3 (without NaCl) 2.0 ml 3M NaCl 9.835 ml sterile distilled water.  
 
20 mM Z-Phe-His-Leu stock: 
110 mg Z-Phe-His-Leu-OH (Bachem) (Mw= 549.63) dissolved in 1.0 ml 0.28 N 
NaOH. Then added: 9.0 ml sterile distilled water in a drop-wise fashion to prevent    
precipitation aliquoted into 1.0 ml Eppendorf tubes and stored aliquots at-20°C until 
use. 
 
Standard Curve for K(Dnp)PPGK(Abz) Substrate 
The change in fluorescence from the baseline levels (before addition of APP) to total 
hydrolysis of a range of substrate concentrations (0.-2.5moles) was measured at the 
excitation and emission wavelength of 320 and 420 nm respectively.  A standard curve 
was generated by plotting this change in fluorescence versus nmoles of substrate 
hydrolysed. The slope was determining using a linear regression curve plotted with 
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